Early-Life Gut Inflammation Drives Sex-Dependent Shifts in the Microbiome-Endocrine-Brain Axis

Olivia Sullivan[1,2,†], Claire Sie[3,†], Katharine M. Ng[3], Sophie Cotton[3], Cal Rosete[2], Jordan E. Hamden[2,4], Ajay Paul Singh[5], Kristen Lee[2,4], Jatin Choudhary[2], Jennifer Kim[1,2], Huaxu Yu[6], Charlotte A. Clayton[3], Natalia A. Carranza Garcia[3], Kateryna Voznyuk[2], Brian D. Deng[3], Nadine Plett[2], Sana Arora[2], Hans Ghezzi[7], Tao Huan[6], Kiran K. Soma[1,2,8], John-Paul J. Yu[5], Carolina Tropini[3,9,10]*, Annie Vogel Ciernia[1,2,4]*

[1]Graduate Program in Neuroscience, University of British Columbia, Vancouver, Canada
[2]Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, Canada
[3]Department of Microbiology & Immunology, University of British Columbia, Vancouver, Canada
[4]Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, Canada
[5]Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
[6]Department of Chemistry, University of British Columbia, Vancouver, Canada
[7]Department of Bioinformatics, University of British Columbia, Vancouver, Canada
[8]Department of Psychology, University of British Columbia, Vancouver Canada
[9]School of Biomedical Engineering, University of British Columbia, Vancouver, Canada
[10]Humans and the Microbiome Program, Canadian Institute for Advanced Research (CIFAR), Toronto, Canada

[†]Co-first authors

*Corresponding Authors:

Carolina Tropini

Life Sciences Centre, Rm 3557
2350 Health Sciences Mall
Vancouver, British Columbia V6T 1Z3

carolina.tropini@ubc.ca

Annie Vogel Ciernia
Centre for Brain Health
2215 Wesbrook Mall
Vancouver, BC V6T2A1
annie.ciernia@ubc.ca

CRediT authorship contribution statement:

OS: Methodology, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing, Visualization
CS: Methodology, Formal Analysis, Investigation, Writing - Original Draft, Writing - Review & Editing, Visualization
KN: Methodology, Formal Analysis, Investigation, Data Curation
SC: Investigation, Data Curation, Writing - Review & Editing
CR: Methodology, Formal Analysis, Investigation, Data Curation, Writing - Original Draft, Writing - Review & Editing
JEH: Investigation, Formal Analysis, Writing - Original Draft, Writing - Review & Editing
APS: Investigation, Formal Analysis
KL: Methodology, Investigation
JC: Investigation, Formal Analysis
JK: Investigation, Writing – Review & Editing
HY: Investigation, Formal Analysis
CAC: Investigation, Data Curation
NACG: Methodology
BDD: Investigation
NP: Formal Analysis
KV: Investigation
SA: Investigation
HG: Investigation, Writing – Review & Editing
TH: Formal Analysis
KS: Methodology, Writing - Review & Editing
JP: Resources, Writing – original draft, Writing– review & editing, Supervision, Project administration, Funding acquisition
CT: Conceptualization, Resources, Writing – original draft, Writing– review & editing, Supervision, Project administration, Funding acquisition.
AVC: Conceptualization, Resources, Visualization, Writing – original draft, Formal Analysis, Writing– review & editing, Supervision, Project administration, Funding acquisition.

Declarations of interest: none

Word count: 13,787

Keywords: gut-brain axis, inflammatory bowel disease, gut inflammation, microglia, androgens, sexual behaviours, microbiome, development

Highlights

Early-life gut inflammation produces sex-specific effects on i) microbiome, ii) sex hormones and iii) behaviour.

Both sexes show disrupted gut bacterial members that regulate sex hormone levels.

Male mice demonstrate deficits in mate seeking, which may be mediated by reduced androgen levels.

Both male and female mice demonstrate shifts in hippocampal microglial morphology.

Abstract

Despite recent advances in understanding the connection between the gut microbiota and the adult brain, there remains a wide knowledge gap in how gut inflammation impacts brain development. We hypothesized that intestinal inflammation in early life would negatively affect neurodevelopment through dysregulation of microbiota communication to the brain. We therefore developed a novel pediatric chemical model of inflammatory bowel disease (IBD), an incurable condition affecting millions of people worldwide. IBD is characterized by chronic intestinal inflammation, and has comorbid symptoms of anxiety, depression and cognitive impairment. Significantly, 25% of patients with IBD are diagnosed during childhood, and the effect of chronic inflammation during this critical period of development is largely unknown. This study investigated the effects of early-life gut inflammation induced by DSS (dextran sulfate sodium) on a range of microbiota, endocrine, and behavioral outcomes, focusing on sex-specific impacts. DSS-treated mice exhibited increased intestinal inflammation, altered microbiota membership, and changes in microbiota-mediated circulating metabolites. The majority of behavioral measures were unaffected, with the exception of impaired mate-seeking behaviors in DSS-treated males. DSS-treated males also showed significantly smaller seminal vesicles, lower circulating androgens, and decreased intestinal hormone-activating enzyme activity. In the brain, microglia morphology was chronically altered with DSS treatment in a sex-specific manner. The results suggest that early-life gut inflammation causes changes in gut microbiota composition, affecting short-chain fatty acid (SCFA) producers and glucuronidase (GUS) activity, correlating with altered SCFA and androgen levels. The findings emphasize the developmental sensitivity to inflammation-induced changes in endocrine signalling and underscore long-lasting physiological and microbiome changes associated with juvenile IBD.

Introduction

Inflammatory bowel disease (IBD) is a group of chronic gastrointestinal (GI) tract conditions that affects over 6.8 million people globally and remains incurable (Alatab et al., 2020). The risk of IBD is correlated with industrialization and, as such, is globally rising in prevalence (Kaplan and Windsor, 2021). Genetic factors account for less than one-third of IBD risk, underscoring the importance of environmental factors such as gut microbiota composition, dietary habits, smoking, and stress levels on disease development (Ananthakrishnan, 2013; Ye et al., 2015). Individuals with IBD frequently undergo cycles of intense inflammatory flare-ups and remission periods (Roda et al., 2020). Over 25% of patients with IBD are diagnosed during childhood or adolescence with symptoms that persist through adulthood (Däbritz et al., 2017). Importantly, little is known about the specific impacts of pediatric-onset IBD on the developing brain. Children and adolescents with IBD have an increased risk of developing anxiety and depression, experience a lower quality of life, and face educational and social challenges along with mild cognitive impairments (Attree et al., 2003; Mackner et al., 2013; Thavamani et al., 2019). Furthermore, neuroimaging studies in adult female and male patients with IBD have revealed

altered brain structure and function (Bao et al., 2015; Lv et al., 2017) some of which correlate with neuropsychiatric impairments (Hou et al., 2020), highlighting the need for similar research in pediatric populations.

Research into inflammatory phenotypes through various animal models – including genetic, chemically induced, and adoptive transfer T cell models – has significantly advanced our understanding of IBD (Wirtz and Neurath, 2007). The widely-used dextran sodium sulfate (DSS)-induced colitis model damages the gut epithelial lining and mimics the gut inflammation and microbiota changes seen in human ulcerative colitis (UC), one of the two main types of IBD (Chassaing et al., 2014). Adult mice treated with DSS have increased anxiety (Nyuyki et al., 2018) and reduced sucrose preference, indicative of a depression endophenotype (Zhou et al., 2023). Additionally, active gut inflammation in adult mice led to anxiety-like behavior and recognition memory impairments (Emge et al., 2016) and social impairments (Brown et al., 2024). Importantly, anxiety and memory deficits were reversed upon resolution of acute inflammation (Emge et al., 2016), which is encouraging for therapeutic resolution of neurophysiological symptons in humans with IBD. While DSS-colitis studies predominantly focus on adult rodents and capture many of the extraintestinal manifestations of IBD seen in adult human patients, research in juvenile rodent models remains limited. In contrast to adult mice, a recent DSS-colitis model in juvenile mice revealed persistent cognitive deficits and anxiety-like behaviors even upon GI-symptom resolution (Salvo et al., 2020). These observations suggest that GI inflammation during developmental periods may have unique and long-lasting effects on brain development, leading to distinct behavioral impacts in adulthood.

How GI inflammation triggers brain and behavior dysfunction is not well understood, but is theorized to involve altered signaling along the gut-brain-axis. The gut microbiota can signal to the brain by immune cell trafficking, peripheral nerve activity, and release of metabolites that circulate to the brain (Banfi et al., 2021; Günther et al., 2021). One of the key brain cells responsive to gut microbe derived metabolites are microglia, the brain's resident innate immune cells. Microglia sculpt synaptic physiology during brain development (Sullivan and Ciernia, 2022), are acutely sensitive to changes in microbiota in early life (Erny et al., 2015; Thion et al., 2017) and are chronically functionally altered from early life inflammation (Vogel Ciernia et al., 2018). Microbiota-derived short chain fatty acids (SCFAs) can enter the blood stream and cross the blood brain barrier to impact microglia development and function (Cryan and Dinan, 2012; Erny et al., 2015; Sullivan and Ciernia, 2022). In both adult and juvenile IBD mouse models, microglia adopt a pro-inflammatory phenotype characterized by altered cellular morphology and increased pro-inflammatory cytokine secretion (Caetano-Silva et al., 2024; Gampierakis et al., 2021; Salvo et al., 2020; Sroor et al., 2019; Talley et al., 2021). Together, this suggests that early life changes to microbiota-derived signalling to brain microglia may negatively impact brain development in IBD.

Beyond impacting brain function and behavior, pediatric IBD poses several unique challenges in other aspects of development, including delayed onset of puberty in both males and females (Ballinger et al., 2003). While undernutrition was inititally thought to be the main driver of delayed puberty, restoring nutritional status fails to normalize the timing of puberty onset, suggesting the involvement of additional factors (Azooz et al., 2001; Brain and Savage, 1994; DeBoer et al., 2010; Deboer and Li, 2011). Animal models of IBD have linked intestinal inflammation to disruption in testosterone levels, estrogen receptor function, and reproductive

organ size, with effects that extend beyond what is seen with undernutrition alone (Azooz et al., 2001; Ballinger et al., 2003; DeBoer et al., 2010; Deboer and Li, 2011). Similarly, findings in human studies show that some patients with IBD (Klaus et al., 2008; Tigas and Tsatsoulis, 2012) and irritable bowel syndrome (Rastelli et al., 2022) have disrupted sex hormone levels and higher rates of sexual dysfunction (Chen et al., 2024; Gaidos et al., 2020). One connection between inflammation and altered hormone levels is thought to be mediated by the gut microbiota, which acts as a regulator of estrogen and androgen synthesis and metabolism (Colldén et al., 2019; He et al., 2021; Maffei et al., 2022; Neuman et al., 2015). In mouse models of IBD, the loss of bacterial species such as *Faecalibacterium prausnitzii* (Sokol et al., 2008) and *Roseburia hominis*, known for producing anti-inflammatory SCFAs, is associated with changes in sex hormone levels (Sui et al., 2021; Torres et al., 2018). The depletion of specific bacteria such as *F. prausnitzii* in IBD, which are crucial for converting estrogen to its active form, can directly impact hormone availability, potentially affecting the onset and progression of sexual development (Ervin et al., 2019). Additionally, the recent discovery of testosterone-degrading bacteria such as *Mycobacterium* contributing to inflammation in IBD underscores the microbiota's profound impact on sexual development, suggesting avenues for targeted microbial interventions to mitigate impairments in IBD (Li et al., 2022; Naser et al., 2014). Altogether, these studies highlight the complex relationships between the gut microbiota and sexual development (Lavelle and Sokol, 2020; Machiels et al., 2014).

There is a critical gap in understanding the interactions between early life intestinal inflammation, brain function, and reproductive development. To bridge this gap, here we introduce a mouse model of pediatric-onset IBD that captures recurrent episodes of gut inflammation throughout childhood and adolescence, modeling the human condition. In both sexes, we assessed the acute and chronic effects of early-life gut inflammation on gut microbiota composition, short-chain fatty acid production, a wide variety of behaviors, sex steroid levels, brain white matter tract integrity and microglial morphology, offering a comprehensive view of IBD's impact on juvenile development. Our findings reveal novel sex-specific changes in reproductive behavior, alterations in microbiota metabolites and hormone signaling, and microglial morphology adaptations. These results highlight the unique long-term consequences for human patients with early-onset IBD, emphasizing a need for early diagnosis and microbiome-targeted intervention strategies.

Methods

Animals

Experimentally naïve 3-week-old C57BL/6J wildtype mice (strain #000664, Jackson Laboratories) were housed in groups of 3-5 with sex and treatment-matched cage mates. Mice were housed in ventilated cages under a 12:12 light-dark cycle with lights on at 0700h and lights off at 1900h in a temperature (22ºC) and humidity (40-60%) controlled environment. Purina LabDiet 5k67 diet and reverse osmosis chlorinated water were given *ad libitum* throughout the experiment unless stated otherwise for specific tasks. All housing conditions and testing procedures were in accordance with the guidelines of the Canadian Council on Animal Care, and all protocols were approved by the Animal Care Committee of the University of British Columbia *(protocols A19-0078, A23-0115, and A23-0086).*

210 *Pediatric IBD mouse model*

211 Mice randomly assigned to the treatment groups were administered three rounds of 5-day
212 treatments of 3-3.5% colitis-grade DSS (36-50 kDa, MP Biomedicals #160110) while the vehicle
213 control group (VEH) received water only. Due to the reported batch-dependent effects of DSS,
214 the optimal concentration of DSS to cause colitis was determined in preceding pilot experiments
215 (Eichele and Kharbanda, 2017). The treatment periods occurred during postnatal days (P) P21-
216 26, P42-47, and P63-68 (Figure 1A). During treatment and for three days following each
217 treatment, mice were weighed daily to monitor for weight loss (Supplemental Table 2). Regular
218 monitoring of weight was continued during the recovery period intervals. One cohort of mice
219 was euthanized three days after the final DSS treatment on P71 (n=4-5/treatment/sex). The
220 remaining two cohorts of mice underwent behavioral testing as young adults between P85-P130
221 (n=11-13/treatment/sex).

222 *Serum and organ collection*

223 Animals were deeply anesthetized with 5% isoflurane, and blood was collected by cardiac
224 puncture. Whole blood was collected into BD Microtainer™ Serum Separator Tubes (BD) and
225 allowed to coagulate for at least 30 minutes at room temperature according to manufacturer
226 instructions. To isolate serum for later analyses, blood samples were spun down at 1200 x g for
227 20 minutes at 4ºC, and the serum was removed and placed in a new tube for storage at -80ºC.
228 Animals were then transcardially perfused with 1X phosphate buffered saline (PBS). Intestinal
229 measures were conducted as follows: first, intestines were dissected out from the gastroduodenal
230 junction to the rectum. Colon length was then measured from the ileocecal junction to the
231 rectum. The contents of the cecum were gently scraped and collected into a sterile tube, then
232 immediately flash-frozen on dry ice. The colon was manipulated into rolls in histological
233 cassettes and immediately fixed in freshly prepared Methacarn solution (60% dry methanol, 30%
234 chloroform, 10% glacial acetic acid) (Ng and Tropini, 2021). Brains were collected and drop
235 fixed in 4% paraformaldehyde (PFA) for 24 hours at 4°C and then transferred to 30% sucrose
236 solution and kept at 4°C until sectioned. For brain connectivity analysis, mice were perfused
237 with PBS followed by 4% PFA and brains were dissected out and then stored in 4% PFA until
238 scanning.

239 *Gut staining and histological scoring*

240 Within 2 weeks of fixation in Methacarn solution, intestinal tissues were processed and
241 infiltrated with paraffin wax as previously described (Ng and Tropini, 2021). Briefly, tissues
242 were washed twice with absolute methanol for 30 minutes each, followed by two washes with
243 absolute ethanol for 20 minutes each. Next, tissues were washed twice with xylene for 15
244 minutes before being placed in melted paraffin wax and incubated for 2 hours at 60ºC. Samples
245 were then sent to the BC Children's Hospital Histology Core for embedding in paraffin wax and
246 sectioning into 4 – 5 µm sections. Histological staining was performed with hematoxylin and
247 eosin as previously described (Stahl et al., 2017). Finally, slides were imaged using a
248 PANNORAMIC® MIDI II (3DHISTECH).

249 *Mucus and bacteria visualization*

Visualization of gut microbes was performed as previously described (Ng and Tropini, 2021). Briefly, to deparaffinize tissues, slides were heated at 60ºC in Coplin jars for 10 minutes, followed by incubation in xylene that was pre-warmed to 60ºC. A second xylene wash was performed at room temperature for 10 minutes, then slides were placed in 99.5% ethanol for 5 minutes. After allowing slides to air-dry, tissues were encircled using a liquid blocker PAP pen. FISH probe hybridization solution (20 mM Tris-HCl, pH 7.4; 0.9 M NaCl; 0.1% sodium dodecylsulfate in nuclease-free water) was pre-warmed to 50ºC before addition of Eub-388 (5'-AF488-GCTGCCTCCCGTAGGAGT-3') to a final concentration of 10 ng/µL (Amann et al., 1990). Slides were then incubated for 3 hours at 50ºC in a humid chamber. Following incubation, tissues were washed once with FISH washing buffer (20 mM Tris-HCl, pH 7.4; 0.9 M NaCl, pre-warmed to 50ºC) for 10 minutes at 50ºC, then additionally with 1x PBS. DNA and intestinal mucus were counter-stained using 10 µg/mL DAPI and 40 µg/mL UEA-1-Rhodamine Red respectively in PBS for 45 minutes at 4ºC. Finally, slides were washed thrice with PBS before mounting with ProLong Gold AntiFade mounting medium (Invitrogen). Fluorescence images were captured using a Zeiss LSM900 confocal microscope using a 100x objective lens.

Microbiome sequencing and analysis

Microbiome composition was determined via sequencing of the 16S rRNA hypervariable region. Total DNA was extracted from 30-60 mg of cecal contents using the DNeasy PowerSoil Pro kit (Qiagen) in accordance with manufacturer protocols. Quantification of extracted DNA concentration prior to library preparation was performed using the Quant-iT™ dsDNA HS Assay (Thermo Fisher). 16S library preparation was conducted at either the Gut4Health facility at BC Children's Hospital or the Biofactorial High-Throughput Biology (Bio!) Facility at the University of British Columbia. For samples collected 3 days after cessation of DSS, library preparation targeting the V4 hypervariable region of the 16S rRNA gene was performed at the Gut4Health facility using established protocols (De Wolfe and Wright, 2023). Amplification of the V4 region was performed with 515F/926R primers (515F, 5'-GTGYCAGCMGCCGCGGTAA-3'; 926R, 5'-CCGYCAATTYMTTTRAGTTT-3'). Pooled libraries were then submitted to the Bio! facility, where sequencing was performed on the Illumina MiSeq™ platform with v2 2 x 250 bp paired-end read chemistry. For all other samples, library preparation targeting the V4-V5 16S rRNA genes was performed at the Bio! Facility as previously described (Ng et al., 2023), and sequencing was run on the Illumina MiSeq™ platform with v3 2 x 300 bp paired-end read chemistry. FASTQC (Andrews, 2010) was run on the generated FASTQ files to assess read quality. Reads were then imported into QIIME2-2023.2 for subsequent analyses (Bolyen et al., 2019). Denoising and quality filtering was performed using DADA2 (via q2-dada2), and reads were trimmed to remove primer sequences while maintaining mean Phred quality scores >Q30 (Callahan et al., 2016). Multiple sequence alignment and phylogenetic tree generation was performed using MAFFT (via q2-alignment) and FastTree2 respectively (via q2-phylogeny) (Katoh et al., 2002; Price et al., 2010). Using the QIIME classification plugin (q2-feature-classifier), amplicon sequence variants (ASVs) were classified via a naïve Bayes machine-learning taxonomic classifier against the SILVA 138 99% identity reference sequence database (Quast et al., 2013).

Further analyses were conducted using R v4.2.2 (R Core team, 2021). Analyses were visualized through the tidyverse (Wickham et al., 2019) and ggplot2 (Hadley, 2016) packages. For sample rarefaction, calculation, and visualization of alpha and beta diversity metrics, the phyloseq

294 (McMurdie and Holmes, 2013), ggpubr (Kassambara, 2023), and vegan (Dixon, 2003) packages
295 were employed. Differential abundance analysis (DAA) was conducted using the
296 metagenomeseq package (Paulson et al., 2013) and Analysis of Composition of Microbiomes
297 (ANCOM) (Mandal et al., 2015) packages through the microbiomeMarker package (Cao et al.,
298 2022). The relative abundance of those taxa identified as significantly differentially abundant
299 were then plotted with FDR-corrected p-values obtained with metagenomeseq. Differentially
300 abundant taxa were plotted using the ComplexHeatmap (Gu et al., 2016) package. The relative
301 abundance of select differentially abundant taxa was then plotted against serum hormone and
302 SCFA concentrations, and Spearman's correlation was calculated using smplot2 (Min and Zhou,
303 2021).

304 *Behavior testing*

305 All behavior testing was performed under white light (600 lux) between the hours of 0900-1800
306 except for the sucrose preference test, which is a 24-hour task. Animals were habituated to the
307 researchers after the anxiety tasks but prior to all other tests through 3 days of handling (1-2
308 min/mouse). For each behavior task, animals were first habituated to room conditions for 30
309 minutes before testing. For all tasks that did not involve bedding, the apparatus was cleaned with
310 diluted saber solution (Vert-2-Go saber diluted 1:16 in water) between mice and between stages.
311 ANY-maze tracking software (Stoelting) was used to record videos and track animal movement
312 during the task. Mice began testing 17 days following the final round of DSS with the exception
313 of a subset cohort, which underwent only the urine preference test and mating behavior test
314 beginning 28 days following the final round of DSS treatment.

315 <u>Urine Preference Test (UPT)</u>
316 Mice were placed in the centre of an open-top box (40 cm x 40 cm x 40 cm, L x W x H)
317 containing two 10 cm diameter inverted pencil cups in opposite corners. A petri dish with
318 blotting paper (1 cm^2) was placed under each pencil cup. Mice were given a 10-minute
319 habituation period where 20 µL of deionized water was dropped onto both blotting papers.
320 Following habituation, mice were given another 10-minutes to explore the two cups, this time
321 with 20 µL of pooled male or female C57BL/6 mouse urine dropped onto one of the blotting
322 papers and 20 µL of deionized water dropped onto the other. In the final stage, mice were given
323 another 10-minutes to explore the two cups, with the urine cup location and urine sex switching
324 from the previous stage (Malkesman et al., 2010). Presentation order of same or opposite sex
325 urine as well as location of urine in the first and second stages was counterbalanced across mice
326 and treatment conditions. ANY-maze tracked the total investigation time when the test mouse's
327 nose was within 1 cm of the inverted pencil cup. Exclusion criteria for data collected during the
328 urine preference test include side preference during habituation (defined as a discrimination
329 index (DI) over 20 or under -20, where DI is the difference in time spent investigating the
330 stimulus cups divided by the total time spent investigating) and side preference exceeding three
331 standard deviations from the mean.

332 <u>Mounting Behavior</u>
333 Sexually inexperienced VEH- and DSS-treated male mice were paired with a novel sexually
334 experienced C57BL/6 female mouse in an empty 35 cm x 20 cm x 15 cm (L x W x H) clear
335 plastic box. ANY-maze (Stoelting) was used to record a 15-minute free interaction period.
336 Videos were hand-scored for the frequency and duration of male mounting by a researcher blind

to treatment conditions. Mounting behavior was defined as male contact with two paws on the front or back of the female as previously described (Bayless et al., 2023).

Open Field Test

The open field was performed in an open-topped grey Plexiglass arena (65 cm x 65 cm x 40 cm; L x W x H). Mice were placed in the centre of the arena and given 20 minutes to freely explore. ANY-maze tracked the total distance travelled and the amount of time spent in the inner and outer zones. The outer zone was defined at 8 cm from the wall of the apparatus.

Elevated Plus Maze

The plus-shaped apparatus was elevated 50 cm above the floor and had two open arms and two closed arms, both 30 cm x 8 cm (L x W). The closed arms were surrounded by 15 cm high walls. Mice were placed in the centre of the apparatus and allowed to freely explore for 5 minutes. ANY-maze tracked the total distance travelled and the amount of time spent in the open arms and closed arms.

Three Chamber Test

The test apparatus was an open-topped rectangular box (60 cm x 40 cm x 22 cm ; L x W x H) divided lengthwise into three identically sized compartments (Yang et al., 2011). The task consisted of three 10-minute phases: habituation, sociability, and social novelty. The sociability and social novelty phases require sex and age matched stimulus mice. The novel mouse was not a cage mate of the familiar mouse in the social novelty phase. Prior to the task, stimulus mice spent 20 minutes/day for 3 days habituating to sitting under inverted pencil cups.

ANY-maze was used to track distance travelled, time in each chamber, and time spent investigating the cup in each phase of the task. When the mouse's nose was within 1 cm of the pencil cup and pointing directly at it, investigation was scored. Looking above or lateral to the cup and climbing on top of the object were not counted as investigation.

Olfaction Habituation-Dishabituation Test

The olfaction test was performed as previously described (Yang and Crawley, 2009). Briefly, mice were habituated to a clean cage without bedding for 30 minutes prior to being repeatedly presented a cotton swab with non-social (vanilla or banana extract diluted 1:1000 in water) and social odours (swab of cage bottom of novel mouse). The order of odour presentation was: water, vanilla extract, banana extract, same sex mice, opposite sex mice. Videos were recorded and hand-scored by researchers blinded to experimental conditions for the time spent investigating each odoured cotton swab, defined as the nose within 1 cm of the swab. Biting and otherwise playing with the cotton swab was not counted as olfaction investigation.

Object Location Memory (OLM) Test

The OLM test was performed in an open-topped Plexiglass square box (40 cm x 40 cm x 40 cm ; L x W x H) lined with bedding ~1 cm in depth. Bedding was kept in the same box each day. One wall of the box was lined with duct tape as a visual cue. The OLM took 8 days in total with 6 days of habituation, 1 day of training and 1 day of testing (Vogel-Ciernia and Wood, 2014). Identical cylindrical spice tins filled with cement were used as training objects and were cleaned with diluted saber solution between trials and allowed to fully dry before re-use. The 5-minute

377 testing phase took place 24 hours after training where one object was moved to a novel location
378 and the other remained in the original training location.

379 ANY-maze tracked the total distance travelled on all 8 days. ANY-maze tracked investigation
380 time and the number of investigations of each object on training and testing days. Investigation
381 time was scored when the mouse's nose was within 1 cm of the object and pointing directly at
382 the object. Looking over or past the object and climbing on top of the object were not counted as
383 investigation. For the training and testing days, a discrimination index (DI) was calculated where
384 DI is the difference in time spent investigating the moved object and the unmoved object divided
385 by the total time spent investigating both objects x100.

386 Mice who had a DI over 20 or under -20 during the training phase were determined as having an
387 innate preference and excluded from final analysis. Mice who explored the objects more or less
388 than 3 standard deviations from the mean were also excluded from analysis as we have done
389 previously (Vogel-Ciernia and Wood, 2014).

390 Self-Grooming and Forced Grooming
391 Mice were individually placed in a new cage without bedding. After a 5 minute habituation
392 period, the cumulative time spent naturally self-grooming was recorded for 5 minutes. The mice
393 were then lightly sprayed with water from a mist bottle and forced self-grooming was scored in
394 the following 5 minutes. All hand scoring of grooming behavior was performed by a researcher
395 blinded to experimental conditions.

396 Forced Swim Test
397 Mice were placed individually into 1 L glass beakers filled with 900 mL of water at a
398 temperature of 23-25°C. Mice were recorded for 6 minutes and then removed from the water as
399 previously described(Can et al., 2011). The last 4 minutes of footage was hand-scored for time
400 spent immobile, defined as the absence of escape-related movements. The hand-scorer was
401 blinded to experimental conditions.

402 *Sex steroid quantification*

403 Serum (10 µl) was pipetted into 2 mL polypropylene bead ruptor tubes with 5 ceramic zirconium
404 oxide beads (Hamden et al., 2021, 2019). Calibration curves (0.05 – 1000 pg), blanks, and
405 quality controls were extracted alongside samples via liquid-liquid extraction and analyzed by
406 specific and ultrasensitive LC-MS/MS as before (Hamden et al., 2021). Progesterone,
407 testosterone (T), androstenedione (AE), 5α-dihydrotestosterone (DHT), and 17β-estradiol (E_2)
408 were measured using multiple reaction monitoring with 2 mass transitions for each analyte.
409 Deuterated internal standards (progesterone-d9, testosterone-d5, and 17β-estradiol-d4) were
410 included in all standards, blanks, controls, and samples to correct for analyte loss and matrix
411 effects. Steroid concentrations were acquired by a Sciex 6500 Qtrap triple quadrupole tandem
412 mass spectrometer. A steroid was considered non-detectable if either the quantifier or qualifier
413 transition was not present. If 50% or more of the values in a group were detectable, then missing
414 values were replaced with the lower limit of quantification$/\sqrt{2}$(Handelsman and Ly, 2019)
415 (Handelsman and Ly 2019). DHT and E_2 were non-detectable in all samples, and AE was non-
416 detectable in all female samples.

417 *Brain microglia immunofluorescence staining*

418 After PFA fixation and sucrose cryoprotection, brain hemispheres were embedded in Optimal
419 Cutting Temperature (OCT) compound (Scigen, 23-730-625), cryosectioned at 30 µm, and
420 stored in 1X PBS at 4°C. For staining, free-floating sections were permeabilized with 1X PBS +
421 0.5% Triton X-100 for 5 minutes and then washed 3 x 5 minutes with 1X PBS. Sections were
422 placed in a blocking solution (5% normal donkey serum, and 1% bovine serum albumin
423 dissolved in 1X PBS + 0.03% Triton) for 1 hour at room temperature with gentle shaking and
424 then incubated with anti-IBA1 primary antibody (chicken; Synaptic Systems (234009); 1:1000)
425 for 48 hours. Sections were washed 3 x 5 minutes in 1X PBS + 0.03% Triton and then incubated
426 in a donkey anti-chicken secondary antibody (Alexa Fluor® 488 Jackson ImmunoResearch
427 (703545185); 1:500) and DAPI (Biolegend (422801); 1:1000) for two hours at room temperature
428 on a gentle tilt. Sections were washed 3 x 5 minutes in 1X PBS + 0.03% Triton and 1x 5 minutes
429 in 1X PBS and then mounted onto glass slides and coverslipped using Invitrogen ProLong Glass
430 Antifade Mountant (Invitrogen, P36984).

431 *Reverse transcription quantitative polymerase chain reaction*
432 At time of euthanasia, the hippocampus tissue was dissected, snap frozen on dry ice and stored at
433 -80ºC until RNA extraction. Total RNA was isolated and water blanks using a Monarch® Total
434 RNA Miniprep Kit (New England Biolabs, Whitby, ON) and RNA quantity and quality were
435 confirmed by Nanodrop spectrophotometer. Complementary DNA (cDNA) was reverse
436 transcribed using a LunaScript RT Supermix Kit (New England Biolabs, Ipswich, MA). The
437 amount of RNA used for reverse transcription was normalized (227 – 400ng) and experimenters
438 were blinded to treatment group and sex during RNA isolation and cDNA synthesis.
439 Transcripts (*Tlr4, Nod1, Nod2, Il1β, Tnfα, Il6*) were quantified via SYBR Green assays
440 (Integrated DNA Technologies, Inc., Coralville, IA) (Table 1). Relative expression levels of the
441 reference gene and genes of interest were assessed using Luna® Universal qPCR Master Mix
442 (New England Biolabs, Whitby, ON). Samples were run in duplicate. A reference gene (*Hprt*)
443 was measured in each sample. Negative controls (water blanks, no reverse transcriptase controls)
444 confirmed the specificity of assays. Melt curve analyses verified that the expected targets were
445 amplified. One sample was excluded from the Male DSS *Nod1* analysis due to lack of specificity
446 in the melt curve.

Gene	Forward	Reverse
Tlr4	GAAGCTTGAATCCCTGCATAG	AGCTCAGATCTATGTTCTTGGTTG
Il1β	TGGCAACTGTTCCTGAACTCA	GGGTCCGTCAACTTCAAAGAAC
Tnfα	GGGTGATCGGTCCCCAAA	TGAGGGTCTGGGCCATAGAA
Il6	CGATGATGCACTTGCAGAAA	ACTCCAGAAGACCAGAGGAA
Nod1	TTCCTCACATAGCACCTTCAC	TCAATGACTATGGCGTGCAG
Nod2	CGAAGCCAAACCTCCAGAA	TCGCAGAAGGACTCAAGAGA
Hprt	CAGTACAGCCCCAAAATGGTTA	AGTCTGGCCTGTATCCAACA

447 Table 1. RT-qPCR primers.
448 The cycle threshold (Ct) of the reference gene *Hprt* for each treatment group and sex were
449 analyzed by two-tailed t-test to determine whether expression of reference gene differed between
450 VEH and LPS groups. There was no significant difference between VEH and DSS groups for the
451 females nor males (p = .76 and .31, respectively). The mean of the reference gene was used to

calculate the ΔCq and ΔCq values were normalized to the VEH group within each sex. Statistics were run and data were graphed using the fold change for each transcript within each sex. Data were analyzed for an effect of treatment by unpaired t-tests.

Microglial morphology analysis

Slides were imaged using the Zeiss Axioscan7 slide scanner microscope at 20X magnification. Maximum intensity extended depth of focus (EDF) images were acquired from Z-stacks containing 16 slices at a step size of 1 µm. EDF images were created using maximum projection settings and converted to tiffs using ZEN (Zeiss). Maximum projection EDF images compile the pixels of highest intensity at any given z-stack position and construct a new 2D image retaining the 3D information. The hippocampus and hypothalamus anatomical regions were traced using the FASTMAP FIJI plugin with reference to the Allen Brain Atlas (Terstege et al., 2022). Within these segmented regions, microglial morphology was analyzed using the pipeline described in Kim et al., 2024 using MicrogliaMorphology (ImageJ tool) and MicrogliaMorphologyR (R package) (Kim et al., 2024a) which uses Image-J plugins Skeletonize (2D/3D) and AnalyzeSkeleton (2D/3D) (Arganda-Carreras et al., 2010) to collect 27 metrics of morphology per microglial cell (Supplemental Figure 4A). We conducted dimensionality reduction using principal component analysis followed by k-means clustering on the first three principal components (Supplemental Figure 4C) to define four morphological classes within our dataset (hypertrophic, rod-like, ramified, ameboid). We identified the optimal clustering parameter using exploratory data analysis methods including the within sum of squares and silhouette methods (Supplemental Figure 4B). We assigned cluster identities by examining the relationship between each cluster and the 27 morphological features (Supplemental Figure 4D) and by using the ColorByCluster feature in MicrogliaMorphology to visually examine the different cluster morphologies (Figure 7A).

We then calculated the percentage of cells in each morphology cluster for each treatment and sex using the 'clusterpercentage' function within MicrogliaMorphologyR. To assess how cluster membership changes with treatment for each sex, we fit a generalized linear mixed model using a beta distribution to model the percentage of cluster membership as a factor of Cluster identity and DSS treatment with MouseID as a repeated measure ("percentage ~ Cluster*treatment + (1|MouseID)") using the `stats_cluster.animal` function from MicrogliaMorphologyR, which is wrapped around the glmmTMB R package (Brooks et al., 2017). We ran a 2-way Analysis of Deviance (Type II Wald chisquare test) test on the model to assess the contribution of Cluster and treatment interactions. Tests between treatment conditions were corrected for multiple comparisons across Clusters (~treatment|Cluster) using the Sidak method and q-values < 0.05 were considered statistically significant.

Short and medium chain fatty acid quantification

Serum samples were stored in -80 freezer prior to lipid extraction. A total of 50 µL of serum was mixed with 450 µL ice-cold methanol, vortexed for 10 seconds, and incubated at -20 ºC for 4 hours for protein precipitation. Samples were then centrifuged at 14,000 rpm at 4 ºC for 15 minutes, and the supernatant were collected and dried down via SpeedVac at 4 ºC. The dried extract was reconstituted in 100 µL of water and acetonitrile solution (1:1, v:v) for LC-MS analysis. Quality control (QC) samples were prepared by pooling 20 µL aliquot from each sample to monitor the instrument performance and optimize the injection volume. A method blank sample was prepared using the identical analytical workflow but without serum. An UHR-

494 QqTOF (Ultra-High Resolution Qq-Time-Of-Flight) Impact II (Bruker Daltonics, Bremen,
495 Germany) mass spectrometry interfaced with an Agilent 1290 Infinity II Ultrahigh-Performance
496 Liquid Chromatography (UHPLC) system (Agilent Technologies, Santa Clara, CA, USA) was
497 used for analysis. LC separation was achieved using a Waters reversed phase (RP) UPLC
498 Acquity BEH C18 Column (1.7 µm, 1.0 mm ×100 mm, 130 Å) (Milford, MA, USA) maintained
499 at 25 °C. The mobile phase A was 5% ACN in H_2O with 10 mM ammonium acetate (pH = 9.8,
500 adjusted ammonium hydroxide) and the mobile phase B was 95% ACN in H_2O. The LC gradient
501 was set as follow: 0 min, 5% B; 8 min, 40% B; 14 min, 70% B; 20 min, 95% B; 23 min, 95% B;
502 24 min, 5% B; 33 min, 5% B. The flow rate was 0.1 mL/min. Negative ion mode was applied
503 with the following MS settings: dry gas temperature, 220 °C; dry gas flow, 7 L/min; nebulizer
504 gas pressure, 1.6 bar; capillary voltage, 3000 V. External calibration was applied using sodium
505 formate to ensure the *m/z* accuracy before sample analysis.

506 SCFA and MCFA measurements from cecal contents were obtained as follows. In brief, 20-40
507 mg of cecal contents were mixed with 0.4 – 0.8 mL of 25% phosphoric acid in water (LabChem).
508 Sample mixtures were thoroughly homogenized via vortexing, then centrifuged at 15,000 x g for
509 10 minutes at 4ºC. Following centrifugation, the sample supernatant was transferred to a new
510 tube, then centrifuged again at 15,000 x g for 10 minutes at 4ºC. The resulting supernatant was
511 then frozen at -20ºC before being sent to the University of Alberta Agricultural, Food &
512 Nutritional Science (AFNS) Chromatography Facility for volatile fatty acid (VFA) analysis using
513 gas chromatography/mass spectrometry (GC/MS) as previously described (Ng et al., 2023).
514 There, the supernatant was filtered through 0.45 µm filters and mixed in a 4:1 ratio with internal
515 standard solution (24.5 mmol/L isocaproic acid). The samples were then injected into a
516 Stabilwax-DA column (length: 30 m, inner diameter: 0.53 mm, film thickness: 0.5 µm, Restek
517 Corporation) on a Bruker Scion 456 GC with a model 8400 autosampler (Bruker Ltd) using a
518 helium carrier gas. The samples were run using a 10 mL/min constant flow with a 5:1 split ratio
519 with a column temperature gradient as follows: 80ºC initial temperature, immediately increased
520 to 180ºC at 20ºC/min, then held for 3 min at 180ºC. The injector and detector temperature were
521 at 250ºC. The peaks were analyzed using CompassCDS software. The concentration of
522 SCFAs/MCFAs per sample was then normalized to mass of the cecal contents for statistical
523 testing.

524 *Bacterial culturing and preparation for SCFA quantification*

525 Selected bacterial strains (Table 2) from public culture collections and lab strain libraries were
526 cultured anaerobically in a vinyl anaerobic chamber maintained with an atmosphere of 5% CO_2,
527 5% H_2, and 90% N_2 for 1-5 days (Coy Lab Products, Grass Lake, MI, USA) on pre-reduced
528 Anaerobic Akkermansia Media plates (AAM:18.5 g/L Brain Heart Infusion, 5.0 g/L Yeast
529 Extract, 8.5 g/L Tryptone, 1.5 g/L Soytone, 2.5 g/L NaCl, 3.75 g/L K_2HPO_4, 1.75 g/L *D*-glucose,
530 0.4 g/L Na_2CO_3, 1.0 mg/L Hemin, 0.5 g/L L-Cysteine HCl, 0.5 mg/L Vitamin K1, and 3% v/v
531 heat-inactivated fetal calf serum supplemented with 15 g/L Agar) until visible colonies were
532 observed. Subsequently, strains were inoculated in AAM for 3 days (or 1 day for fast-growing
533 strains) before being centrifuged at 6000 xg for 5 minutes to remove bacteria. 1 mL of bacterial
534 supernatants was then combined with 200 µl of 25% v/v phosphoric acid before being frozen and
535 quantified at the AFNS Chromatography Facility as described above.

Strain	**Culture Collection**	**Reference number**

Eubacterium eligens	DSMZ	3376
Eubacterium ventriosum	DSMZ	3988
Eubacterium hallii	DSMZ	3353
Eubacterium biforme	DSMZ	3989
Eubacterium rectale	ATCC	33656
Roseburia inulinivorans	DSMZ	16841
Ruminococcus lactaris	ATCC	29176
Ruminococcus torques	ATCC	27756
Ruminococcus gnavus	ATCC	29149
Ruminococcus bromii	ATCC	27255
Lactobacillus salivarius HA-118	Probiotic	
Lactobacillus acidophilus A118	Probiotic	
Lactobacillus reuteri NM12	CIAMIB	(Wong et al., 2022)
Lactobacillus murinus NM26	CIAMIB	(Wong et al., 2022)
Lactobacillus murinus NM28	CIAMIB	(Wong et al., 2022)
Lactobacillus johnsonii NM60	CIAMIB	(Wong et al., 2022)
Lactobacillus intestinalis NM61	CIAMIB	(Wong et al., 2022)
Akkermansia muciniphila	ATCC	BAA-835
Escherichia coli NM84	CIAMIB	(Wong et al., 2022)
Bacteroides thetaiotaomicron 8702		(Han et al., 2021)
Bacteroides thetaiotaomicron 8713		(Han et al., 2021)
Bacteroides thetaiotaomicron 3731		(Ng et al., 2023)
Bacteroides thetaiotaomicron VPI 5482		(Ng et al., 2023)

Table 2. Cultured bacterial strains used for *in vitro* SCFA measurements.

Bacterial metagenomics shotgun sequencing and analysis

DNA from cecal contents collected from mice 3 days after cessation of the third round of DSS was extracted and quantified as described above in "*Microbiome sequencing and analysis"*. Shotgun metagenomics library preparation was done using the Illumina DNA Prep library preparation kit in accordance with manufacturer instructions, and sequencing was then performed on the Illumina NextSeq™ platform with 2x150 bp paired-end read chemistry. Library preparation and sequencing were performed at the UBC Sequencing + Bioinformatics Consortium.

For shotgun sequencing analysis, the quality of raw reads was evaluated using FASTQC v0 12.1 (Andrews, 2010) and MultiQC v 1.19 (Ewels et al., 2016). Data was then run through SqueezeMeta v 1.6.5 pipeline in coassembly mode (Tamames and Puente-Sánchez, 2019). The coassembly method pools reads from all samples to create a single shared metagenome assembly. Briefly, sequences were trimmed and quality-filtered using Trimmomatic (Bolger et al., 2014); metagenome assembly was performed using Megahit (Li et al., 2015); ORF and rRNA prediction was done using Prodigal (Hyatt et al., 2010) and barrnap (Seemann, 2024), respectively before classification was performed using RDP classifier (Wang et al., 2007); Diamond software (Buchfink et al., 2015) was used to assign taxonomy against the Genbank nr database, COGs/NOGs against the eggNOG database (Huerta-Cepas et al., 2016) and KEGG ID against the KEGG database (Kanehisa and Goto, 2000); gene coverage and abundance

estimation were performed by mapping individual reads to the reference coassembly contig using Bowtie2 (Langmead and Salzberg, 2012). Finally, SqueezeMeta outputs were analyzed using the SQMTools package (Puente-Sánchez et al., 2020). Normalization of gene abundance was performed using trimmed mean of M-values (TMM) with the edgeR package (Robinson et al., 2009) and plotted using ComplexHeatmap (Gu et al., 2016). The TMM method of normalization can robustly account for differences in sequencing depth between samples by adjusting raw counts using a unique scaling factor for each sample. The scaling factor is derived by comparing gene abundances against a reference sample (which is automatically determined to be the sample that has the 75th percentile of log-counts closest to the median across all samples), then using a weighted trimmed mean over the log-transformed fold-change differences between the sample and the reference.

β-glucuronidase assay

Beta-glucuronidase activity was measured using the QuantiChrom™ β-Glucuronidase Assay Kit (BioAssay Systems, San Francisco, CA, USA). Cecal contents collected from mice acutely following DSS (P71) and after ~40 days of recovery (P110) were processed as follows: 10-50 mg of cecal contents were aliquoted and suspended in 600 µl of sterile dH_2O. Samples were then homogenized at 30 Hz for 2 minutes using the TissueLyser II (QIAGEN) before being centrifuged at 1000 xg for 1 minute at 4ºC to remove cecal debris without pelleting bacteria. The supernatant was then centrifuged at 13000 xg for 5 minutes at 4ºC. The pelleted bacteria were then resuspended in 600 µl of chilled sterile dH_2O and vortexed for 10 seconds. Bacterial lysis was achieved through 3 rounds of sonication at 50 watts for 20 seconds each using an XL2020 sonicator equipped with a Microtip™ (Misonix, Farmingdale, NY, USA). Samples were diluted 1:2-1:10 as needed before performing the β-glucuronidase activity assay according to manufacturer instructions. Enzyme activity was normalized to total protein concentration in each sample, measured using the Pierce BCA Protein Assay Kit (ThermoFisher).

MRI acquisition and data processing

Ex vivo imaging and analysis, including standard data preprocessing and region of interest (ROI) analyses, were performed as previously described (Yi et al., 2019). Briefly, brains were extracted from the cranial vault between P95 and P130 and post fixed in 4% PFA (n = 54;13 vehicle per sex, 14 DSS per sex). Brains were placed in a custom-built holder immersed in Fluorinert (FC-3283, 3M, St. Paul, MN, USA) and imaged with a 4.7-T Agilent MRI system with a 3.5 cm diameter quadrature volume RF coil. Multi-slice, diffusion-weighted, spin echo images were used to acquire 10 nondiffusion weighted images (b=0 s•mm^{-2}) and 75 diffusion-weighted images (25: b=800 s•mm^{-2}, 50: b=2,000 s•mm^{-2}), using non-colinear diffusion-weighting directions. Diffusion imaging was performed with a TE/TR=24.17/2000-ms, FOV=30×30 mm^2, and a matrix=192×192 reconstructed to 256×256 for an isotropic voxel size of 0.25-mm over two signal averages. Raw data files were converted to NIfTI format and FSL was used to correct for eddy current artifacts (Smith et al., 2004). A DTI-based mouse brain atlas (Jiang and Johnson, 2011) was used as a study space template and to define regions of interest (ROI) including the left and right hippocampus, frontal association cortex, striatum, amygdala, thalamus, and hypothalamus. Multi-shell diffusion data were fit with the Microstructure Diffusion Toolbox (MDT) (Harms et al., 2017) to the neurite orientation dispersion and density imaging (NODDI) model (Zhang et al., 2012). An additional compartment of isotropic restriction was included to

account for potential fixative effects as recommended (Alexander et al., 2010). The mean values for neurite density index (NDI) and orientation dispersion index (ODI), which represent indices of intracellular and extracellular diffusion respectively, were calculated in each ROI using Pyradiomics (van Griethuysen et al., 2017) and compared among experimental groups.

Statistical analyses

Statistics and graphs were created with GraphPad Prism 10.1.1 (GraphPad Software), Python 3.8 and RStudio software (RStudio Team, 2022). A repeated measures ANOVA was used to assess body weight changes during treatment. All organ comparisons, SCFA measurements, gut microbial β-glucuronidase (GUS) activity measurements, and almost all behavioral tests were assessed using a two-way ANOVA to assess main effects of treatment and sex and Šidák corrected post-hoc comparisons were performed to determine statistical significance within sex if main effects or interactions were observed. The urine preference test was assessed by comparing each group to chance (50%) using a single sample t-test. To directly compare preferences between treatments, an unpaired two-tailed t-test was conducted. Steroid levels were analyzed by Mann-Whitney U. Statistical significance of alpha diversity metrics (Observed features) was assessed using a two-way ANOVA to assess main effects of treatment and sex. Beta diversity metrics were evaluated using PERMANOVA analysis. FDR-corrected p-values obtained from DAA with metagenomeseq were reported.

For the MRI analysis, a 2 × 2 analysis of variance (ANOVA) was used to determine the effect of treatment, biological sex, and their interactions on the ROI values. The effects of ROI laterality and imaging age effects were regressed from the data before the ANOVA was performed as these effects were not pertinent to the tested hypotheses. Benjamini-Hochberg false discovery rate (FDR) procedure was used to control for multiple hypothesis testing across ROIs within each imaging signal. Statistical significance of an ANOVA is defined as an FDR adjusted p-value <.05. Post-hoc pairwise difference testing was performed using Fisher's LSD test Partial η^2 explains how much of the unexplained variance in the model is described by the addition of that variable into the model. The plotted imaging metric values represent the metric values after the laterality and batch effects have been removed.

Results

An early-life DSS model of pediatric IBD

To establish a model of juvenile-onset IBD that mimics the remitting and recurrent cycles of gut inflammation often observed in juvenile patients with IBD, we administered DSS in drinking water repeatedly across early postnatal development starting on postnatal day 21 (P21) (Figure 1A). Colon length is indicative of inflammatory state, with colon shortening being induced by effective DSS treatment (Chassaing et al., 2014). Three days after the final treatment, colon length was significantly decreased by DSS in both sexes (main effect of treatment ($F(1, 21) = 39.30$, p.0001) (Figure 1B). Both female (p=.009) and male (p=.0002) mice treated with DSS had colon lengths that were significantly shorter than untreated mice, indicating successful induction of intestinal inflammation in our model. Furthermore, body weights were recorded

640 throughout the treatment period (Chassaing et al., 2014) (Figures 1C, D). Female mice showed
641 mild weight loss in response to DSS, with only the second round producing significant decreases
642 from VEH littermates (treatment x day interaction $F(50,714) = 6.693$, $p<.0001$) (Figure 1C).
643 Conversely, male DSS-treated mice showed more dramatic weight loss across the three treatment
644 periods (treatment x day interaction $F(50,686) = 12.372$, $p<.0001$) (Figure 1D). To further
645 investigate inflammation caused by repeated administration of DSS, we examined the
646 histological architecture of colonic tissues using hematoxylin and eosin staining. Following
647 chronic DSS treatment, the gut epithelial layer was disturbed, showing increased crypt length
648 (crypt abscess), depletion of mucus-producing goblet cells, increased incidence of inflammatory
649 cell infiltration, and ruffling of the normally smooth epithelium (Figures 1E, F). Furthermore,
650 UEA-1 lectin staining targeting the intestinal mucus layer revealed that DSS-treated juvenile
651 mice experienced profound alterations in mucus structure, with loss of the normal striated bilayer
652 organization (Ng and Tropini, 2021) (Figure 1F). Finally, to examine changes to gut microbiota
653 composition caused by repeated cycles of early life inflammation, we performed 16S rRNA
654 sequencing targeting the bacterial V4-V5 variable regions. Consistent with previous studies in
655 adult mice, DSS treatment resulted in significant losses to microbiota alpha diversity, with the
656 number of observed features, a proxy for the number of bacterial species present (Kleine
657 Bardenhorst et al., 2022), being significantly decreased in DSS-treated animals compared to
658 vehicle (significant effect of treatment $F(1,12) = 5.3$, $p = .0387$) (Figure 1G) (Munyaka et al.,
659 2016). Similarly, between-group microbiota compositional differences were revealed to be
660 significantly different when compared using calculated Bray-Curtis distance matrices (treatment
661 x sex interaction $F(1,12) = 3.2158$, $p < .046$) (Figure 1H). Altogether, these results suggest that
662 our DSS colitis model of juvenile IBD induces profound physiological and microbiological
663 changes to the gut.



Figure 1. Juvenile mouse DSS treatment models early-life intestinal inflammation. *A*. Experimental schematic. Control mice were given water throughout (VEH), while treatment

667 mice were given 3 rounds of 5-day long DSS treatments beginning at P21, P42, and P63 (DSS).
668 *B.* Post-treatment colon lengths measured at P71, three days after the final round of DSS, were
669 shorter in DSS-treated mice. Each graph bar and error bar represent the mean ± SEM, n=5-
670 7/group. *C, D.* Female and male percent weight change from baseline (P21) starting weight. Each
671 point and error bar represents the mean ± SEM, n=11-13/group. *E.* Representative images of
672 hematoxylin and eosin-stained colonic tissues from mice collected at P71 confirm that DSS
673 treatment induced intestinal inflammation. Scale bar, 100 µm. *F.* Representative fluorescence *in*
674 *situ* hybridization (FISH) images from VEH and DSS treated mice shows gut disruption in DSS
675 treated mice. Scale bar, 100 µm. Colors: host tissue (DAPI, blue), mucus (UEA-1, green), and
676 bacteria (Eub-338, red). *G.* Microbiota alpha diversity as measured by number of observed
677 unique features (a proxy for number of species) per sample is significantly lower in DSS-treated
678 mice, n=3-5/group. *H.* Principal Component Analysis of Bray-Curtis diversity index shows
679 separation by DSS treatment, n=3-5/group. *p<.05. ***p<.0001.

680

681 *Early-life DSS affects self-grooming behavior in male mice*

682 Previous work in early life gut-inflammatory models, including those for IBD, identified altered
683 mouse behavior (Salvo et al., 2020). To fully profile behavioral phenotypes in our pediatric IBD
684 model, we performed a battery of behavioral testing beginning 17 days after DSS treatment to
685 examine anxiety-like (elevated plus maze, light-dark box, open field test), memory (spatial
686 object location), sociability and social memory (three chamber task), repetitive behavior (self-
687 grooming), and depression-like behaviors (forced swim). Unlike previous reports, we did not
688 observe any significant effects of treatment for either sex in most of these tests (Figure 2 and
689 Supplemental Table 1), with the single exception of decreased self-grooming (main effect of
690 treatment ($F(1, 24) = 6.514$, p=.018)) in the DSS-treated males (p=.031). There were no
691 significant main effects of treatment or interactions with treatment on distance travelled or total
692 exploration on any of the tasks (Supplemental Figure 1 and Supplemental Table 1). This suggests
693 that that the majority of behaviors examined are not impacted by previous repeated bouts of
694 postnatal gut inflammation in early-life, potentially due to the normal development of most
695 neuronal circuits prior to treatment beginning at P21.


A
WATER
16 days
Anxiety, Memory, Social, Repetitive & Depressive-Like Behaviour
P130
5 days
DSS
WATER
DSS
WATER
DSS
P21
P42
P63
B
Elevated Plus Maze
Female
Male
% Time in Open Arm
C
Light Dark Box
% Time in Light Box
D
Open Field Test
% Time in Center
E
Object Location Memory
Discrimination Index
F
Three Chamber Social
% Time Investigating Mouse
G
Three Chamber Novel
% Time Investigating Novel Mouse
H
Self Grooming
Time Spent Grooming (s)
*
I
Forced Grooming
Time Spent Grooming (s)
J
Forced Swim Test
% Time Immobile
VEH
DSS

696

697

Figure 2. Early-life DSS treatment has minimal impacts on adult anxiety, social, memory, and depression-like behaviors. *A*. Experimental design. After a 16-day recovery period, a behavioral battery compared VEH and DSS treated mice on *B.* the elevated plus maze (n=10-13/group) *C.* the light dark box (n=11-13/group) *D.* the open field test (n=11-13/group) *E*. the object location memory test (24hr) (n=6-13/group) *F*. the three-chamber social task (n=11-13/group) *G.* the three-chamber novel social task (n=10-13/group) *H.* self-grooming (n=6-8/group) *I*. forced grooming (n=7-8/group) and *J.* the forced swim test (n=11-13/group). All graph bars and error bars represent the mean ± SEM. *p<.05

Early-life DSS disrupts male preference for female odour

To test the impact of repeated bouts of inflammation on sexual behaviors in our model, ~1 month following DSS, mice were given a preference test for same- or opposite-sex urine (Figure 3A). Female VEH- and DSS-treated mice both failed to show a significant preference for either same-sex urine (VEH one sample t-test vs 50% $t(6)$ =0.383, p=.714 or DSS one sample t-test vs 50% $t(6)$ =0.406, p=.70) or opposite-sex urine (VEH one sample t-test vs 50% $t(6)$ =0.350, p=.74 or one sample t-test vs 50% DSS $t(6)$ =0.256, p=.81) compared to water (Figure 3B). In contrast, male VEH-treated mice showed a significant preference for same-sex urine compared to water (one sample t-test vs 50% $t(7)$ = 2.468, p=.04) and a trend for a preference for opposite-sex urine $t(7)$ = 1.972, p=.086. However, male DSS-treated mice failed to show a preference for same-sex urine ($t(7)$ = 1.153, p=.29) as well as opposite-sex urine over water ($t(7)$ = 0.99, p=.36) (Figure 3C). When comparing preferences directly, there was no significant difference in VEH-treated and DSS-treated males in their preference for male urine ($t(14)$ = 1.45, p=.17). However, VEH-treated males showed a significantly higher preference for female urine than DSS-treated males ($t(14)$ = 2.16, p=.048) (Figure 3C). Together, these data demonstrate that DSS treatment produced a significant deficit in opposite-sex scent-seeking behaviors, a key aspect of mate-seeking behavior in male rodents (Malkesman et al., 2010).



Figure 3. Early-life DSS treatment induces male sex-specific impairments in mate-seeking behavior. *A*. Experimental design. After a 30-day recovery period, mate-seeking behavior was

assessed by the Urine Preference Test. *B*. Female mice showed no preference for female or male urine over water and VEH and DSS female mice performed similarly. n=7/group. Each graph bar and error bar represent the mean ± SEM. Dotted line is 50% preference. *C*. Male VEH mice significantly preferred both male and female urine over water (above 50% dotted line). DSS treated males showed no preference for urine over water. n=8/group. *D, E.* Olfactory habituation-dishabituation test for females (*D*) and males (*E*) revealed no differences between DSS- and VEH- treated mice and normal exploration, habituation and then dishabituation patterns for each odour n=6-7/group. *F.* DSS and VEH male mice showed similar number of mounts and latency to first mount a sexually experienced female. n=4-5/group. *$p<0.05$.

To verify that deficits in the urine preference test in DSS-treated males were not due to impairments in olfaction, we performed the olfaction habituation-dishabituation task (Yang and Crawley, 2009). We tested two extract odours (vanilla and banana) and two social odours (one same sex and one opposite sex novel mouse odours). Both treatment groups and sexes showed the expected patterns of active exploration of each odour followed by habituation across repeated trials and then active exploration of the next novel odour (dishabituation) (Figure 3D and E and supplemental Table 1), indicating that DSS treatment did not negatively impact odour processing or recognition. Together, these findings demonstrate a long-term shift in male-specific preferences for female odours following early-life gut inflammation.

To further explore impacts on consummatory mating behaviors, we compared sexually naïve mounting behavior of the VEH- and DSS-treated male mice when paired with a sexually experienced untreated female wildtype control mouse. Over a 15-minute mating session, DSS-treated male mice showed no significant differences in copulatory behaviors compared to VEH males including frequency of mounting ($t(8) = 1.06$, $p=.32$) and latency to first mount ($t(6) = 1.30$, $p=.42$) (Figure 3F). Together, this suggests that early-life DSS treatment has specific deficits on mate-seeking through olfactory cues and not on consummatory sexual behavior.

Early-life intestinal inflammation disrupts androgens in males

Given the observed differences in urine odor preferences, we investigated reproductive organ development in DSS- and VEH- treated mice. Male and female reproductive organs were collected following behavior testing and weighed (P110). In males, there was a significant decrease in the weight of the androgen-sensitive seminal vesicles in the DSS-treated animals compared to VEH ($t(23) = 2.44$, $p=.03$) (Figure 4A). However, there was no significant difference in testes weight between treatments ($t(23) = 1.05$, $p=.30$) (Figure 4B). In females, we observed no difference in uterus weight ($t(23) = 0.42$, $p=.68$) (Figure 4C). To further investigate the impairment in male seminal vesicle development, we examined changes in circulating steroid hormones in VEH- and DSS-treated male mice both acutely (P71, 3 days after final DSS treatment) (Figure 4D, E) and chronically (after behavioral testing, P110) (Figure 4F, G). At the acute timepoint (P71), the DSS-treated males showed a significant decrease in serum testosterone ($U = 0$, $p =.03$) and androstenedione ($U = 0$, $p =.03$) levels. This decrease was maintained through behavioral testing for androstenedione ($U = 27$, $p =.01$) but not for testosterone ($U = 46$, $p =.22$). There were no significant differences in serum progesterone in males at either timepoint and no impacts in females for androstenedione, testosterone, or

progesterone (Supplemental Figure 2). All together, these data indicate that early-life DSS treatment reduces male reproductive organs, potentially through reduced levels of circulating androgens.



Figure 4. Early-life DSS treatment induces male sex-specific impairments in reproductive physiology. *A*. Seminal vesicles were significantly lower in weight in DSS-treated male mice than VEH-treated mice at P110. n=12-13/group. *B*. There were no significant differences in testes weight between DSS- and VEH-treated males at P110. n=12-13/group. *C*. No significant differences in uterus and ovaries weights between DSS- and VEH-treated females were observed at P110. n=12-13/group. *D-E*. 3 days after the last DSS treatment (P71), male serum testosterone (*D)* and androstenedione (*E*) levels were significantly lower in DSS- than in VEH-treated mice. n=4/group. *F-G*. Following the last behavioral experiment (P110), male serum testosterone (*D)* levels were not significantly different between VEH and DSS mice, but androstenedione (*E*) levels were significantly lower in DSS- than in VEH-treated mice. n=12-13/group. Each graph bar and error bar represent the mean ± SEM. *p<0.05.

Early-life intestinal inflammation alters SCFA/MCFA production and gut microbiome composition to favor decreased abundance of SCFA/MCFA-producing taxa

Since we observed changes in microbiome composition immediately following DSS treatment, we then examined circulating short and medium-chain fatty acids (SCFAs and MCFAs respectively) (Figure 5A), which are produced by the gut microbiota. Importantly, SCFAs are known to be disrupted in patients with IBD and can alter sex steroids (Acharya et al., 2024) and brain function (Cryan and Dinan, 2012; Erny et al., 2015; Sullivan and Ciernia, 2022). Acutely

following the last round of DSS (P71), DSS treatment significantly reduced female ($p = .014$) and male ($p = .037$) serum levels of valeric acid (see Supplemental Table 1 for full statistics). In females, DSS also decreased serum levels of capric acid ($p = .022$) (Figure 5A). Interestingly, we found no significant differences in levels of acetic, propionic, and butyric acid, which are the most abundant SCFAs and play important roles in maintaining intestinal homeostasis (Venegas et al., 2019). We also measured SCFA/MCFA levels in cecal contents, where butyric acid was the only SCFA that was significantly different between VEH- and DSS-treated males ($p = .0498$) (Figure 5B, see Supplemental Table 1 for full statistics). Critically, butyric acid is an important anti-inflammatory agent that is known to be reduced in patients with IBD (Hodgkinson et al., 2023).

We then investigated whether SCFA-producing bacteria were differentially present in VEH- and DSS-treated mice acutely following the last round of DSS at P71 (Figure 5C, Supplemental Figure 3A). Differential abundance analysis revealed that DSS-treated female mice possessed decreased relative abundance of many bacteria genera belonging to the phylum Bacillota (Supplemental Figure 3B, See Supplemental Statistics Table for full list), which contains many SCFA-producing bacterial species (Fusco et al., 2023; Mandal et al., 2015). Indeed, the relative abundance of Bacillota was moderately correlated with cecal acetic ($R = 0.54$, $p = .005$) and butyric acid ($R = 0.76$, $p < .001$) levels (Supplemental Figure 3C). Specifically, DSS-treated mice possessed decreased relative abundance of the genus *Roseburia* ($p_{females} = .0039$, $p_{males} = .0201$) along with several *Eubacterium* groups ([*Eubacterium*] ventriosum group, $p_{females} < .0001$, $p_{males} < .0001$; [*Eubacterium*] xylanophilum group, $p_{females} < .0001$, $p_{males} = .0062$; [*Eubacterium*] coprostanoligenes group, $p_{females} = .0059$, $p_{males} < .0001$) – bacterial taxa that are known to produce SCFAs (Figure 5C, D, Supplemental Figure 3B) (Akhtar et al., 2021; Fusco et al., 2023; Mirzaei et al., 2021; Ziętek et al., 2021). Differential abundance analysis also revealed that the species *Bacteroides thetaiotaomicron* ($p_{females} = .0001$, $p_{males} < .0001$) and *Akkermansia muciniphila* ($p_{females} < .0001$, p_{males} = ns) were enriched in DSS-treated mice, bacteria not known to produce butyric acid (Effendi et al., 2022; Kim et al., 2021). To investigate these correlations, we cultured a variety of strains belonging the above identified taxa, then measured production of SCFAs *in vitro* (Figure 5D). This analysis revealed that *Eubacterium* sp. and *Roseburia sp.* are both capable of producing butyric acid and are depleted following DSS treatment, potentially contributing to the decreased concentration of butyric acid in cecal contents. Interestingly, strains that are both more (*Bacteroides* sp. and *Akkermansia* sp.) and less (*Ruminoccocus* sp. and *Lactobacillus* sp.) abundant after DSS treatment were capable of producing acetic acid, which may contribute to the lack of significant difference in cecal acetic acid concentration following DSS.

Due to the differences observed in mating behaviour and circulating sex hormone levels following DSS treatment, we also examined the potential role of the DSS-altered microbiome in driving these phenotypes. Of the differentially abundant taxa observed, we noted that many have been shown to express β-glucuronidases (GUS) and β-glucosidases, enzymes that convert conjugated hormones to their active form (Ervin et al., 2019; Patel et al., 2023). Strikingly, the relative abundance of several GUS-producing taxa was correlated with serum testosterone and androstenedioine concentrations (Figure 5E). For instance, the relative abundance of [*Eubacterium*] *coprostanoligenes* group was positively correlated with androgen levels (androstenedione, $R = 0.91$, $p = .002$; testosterone, $R = 0.91$, $p = .002$). Similarly, the relative abundance of *Lactobacillus* was positively correlated with serum androstenedione ($R = 0.81$, $p =$

.022) and testosterone (R = 0.90, p = .005). In contrast, the relative abundance of *Bacteroides thetaiotaomicron*, which is known to express a sulfotransferase that can deactivate hormones (Cotton et al., 2023), was negatively correlated with testosterone concentrations (R = -0.74, p = .046) (Supplemental Figure 3D).

Following this observation, we performed shotgun metagenomic sequencing analysis to examine the genomic potential of the microbiota to express hormone-modifying and degrading enzymes (Figure 5F). Supporting the genetic potential of the microbiota in our mice to modify active levels of hormones, we found the presence of genes mapping to various hydroxysteroid dehydrogenases (K00038 and K22418) as well as β-glucuronidase (K01195). Importantly, genomic potential is not a predictor of expression levels or enzyme activity due to various pre- and post-translational regulatory mechanisms. Therefore, we aimed to measure GUS activity directly from cecal contents using a fluorometric molecule conjugated to a glucuronide. Interestingly, GUS activity was significantly decreased in males (p = .0006) following DSS treatment, with activity in females trending lower as well (p = .0856) (Figure 5G). Taken together, these findings indicate that early life inflammation alters microbiome composition, leading to differences in SCFA producers and GUS activity which correlates with SCFA and androgen levels.


A
Serum
VEH
DSS
Females
Males
Relative MS Intensity (%)
Valeric Acid
Capric Acid
Valeric Acid
B
Cecal
Concentration (nmol/mg)
Acetic acid
Propionic acid
Butyric acid
C
Roseburia
[Eubacterium] ventriosum group
Bacteroides thetaiotaomicron
[Eubacterium] coprostanoligenes group
Relative Abundance (%)
VEH DSS VEH DSS
D
Downregulated
Upregulated
Acetic Acid
Propionic Acid
Butyric Acid
L. salivarius HA-118
L. acidophilus A118
L. reuteri NM12
L. murinus NM26
L. murinus NM28
L. johnsonii NM60
L. intestinalis NM61
R. torques ATCC 27756
R. gnavus ATCC 29149
R. lactaris ATCC 29176
R. inulinivorans DSM 16841
E. eligens DSM 3376
E. ventriosum DSM 3988
E. hallii DSM 3353
E. biforme DSM 3989
E. rectale ATCC 33656
B. thetaiotaomicron 8713
B. thetaiotaomicron 8702
E. coli BW25113
E. coli NM84
B. thetaiotaomicron VPI 5482
B. thetaiotaomicron 3731
A. muciniphila ATCC BAA-835
μmol/ml, blank-subtracted
E
Testosterone
Androstenedione
[Eubacterium] coprostanoligenes group
Lactobacillus
Concentration (ng/mL)
R = 0.91, p = 0.002
R = 0.90, p = 0.005
R = 0.81, p = 0.022
Relative Abundance (%)
F
VEH
DSS
K01188; beta−glucosidase [EC:3.2.1.21]
K01235; alpha−glucuronidase [EC:3.2.1.139]
K00038; 3alpha(or 20beta)−hydroxysteroid dehydrogenase [EC:1.1.1.53]
K22418; 11beta/17beta−hydroxysteroid dehydrogenase [EC:1.1.1.146 1.1.1.−]
K01195; beta−glucuronidase [EC:3.2.1.31]
0.002 0.005
26.980 11.498
7.622 26.745
16.417 20.433
107.838 171.295
TMM normalized counts
G
GUS activity (U/mg protein)
VEH DSS VEH DSS

854

855 **Figure 5. Early-life DSS treatment causes decreases in short- and medium-chain fatty acid**
856 **levels and relative abundance of associated microbiota.** *A*. Serum levels of valeric and caproic
857 acid were significantly lower in DSS-treated females compared to VEH at P71. Valeric acid was
858 also significantly lower in DSS-treated male serum. n=4-5/group. See Supplement for full set of
859 serum statistics. *B.* Cecal levels SCFAs at P71, represented in nmol/mg of contents.
860 Concentration of butyric acid was significantly different in DSS-treated males compared to VEH
861 at P71. n=4-5/group. See Supplement for full set of cecal SCFA statistics. *C.* Relative abundance
862 of select SCFA-producing bacteria. n=4-5/group. *D. In vitro* SCFA production from bacterial
863 genera represented in the experimental microbiota. *E.* Correlation of select bacteria with serum
864 testosterone and androstenedione concentrations in males. n=4/group. *F.* Metagenomic
865 abundance of steroid-modifying and steroid-degrading enzymes normalized by TMM, trimmed
866 mean of M-values. Numbers represent mean TMM-normalized counts per treatment for each
867 enzyme. n=4-6/treatment. *G.* GUS activity in cecal contents was significantly lower in DSS-
868 treated males. Activity was measured from cecal contents and normalized to total protein. n=3-
869 5/group. Error bars in bar plots represent SEM. *p<0.05, ***p<.001, ****p<.0001.

870

871 *Early life intestinal inflammation causes long-lasting physiological differences and changes to*
872 *gut microbiota composition*

873 Having observed changes in microbially-produced and modified metabolites and bacterial
874 abundance acutely post-inflammation, we sought to measure whether they persisted into
875 adulthood (P110). We first examined microbiome diversity as an indicator of overall lasting
876 effect of DSS. At P110, the number of observed microbiota features remained significantly
877 decreased in female DSS-treated mice compared to VEH (p = .0207) (Figure 6A). Additionally,
878 although microbiota compositions (as calculated using Bray-Curtis distances) became more
879 similar between DSS-treated and VEH mice, differences in sex and treatment remained
880 significant (PERMANOVA, p_{sex} = .001, $p_{treatment}$ = .004) (Figure 6B). Consistent with these long-
881 lasting microbiota changes, analysis of colon histology revealed that DSS-treated colons at P110
882 retained several indicators of inflammation at sparsely found regions throughout the gut,
883 specifically intestinal crypt hyperplasia and increased immune cell infiltration (representative
884 images shown, Figure 6C). Nevertheless, the majority of the epithelium along the length of the

colon appeared to have recovered after ~40 days post cessation of DSS



Figure 6. Early-life DSS treatment causes long-lasting physiological differences and changes to microbiota composition. *A.* Diversity of microbiota composition ~30 days after cessation of DSS at P110, measured in number of unique features per sample. n=5/group. *B.* Principal Component Analysis of Bray-Curtis diversity index at P110. n=5/group. *C.*

Representative histological images of hematoxylin and eosin-stained colons at P110. *D.* Cecal concentrations of SCFAs at P110. n=5/group. See Supplement for full set of cecal measurements. *E.* Relative abundance bar plots of select SCFA-producing bacteria. n=5/group. *F.* GUS activity in cecal contents at P110. Activity measured from cecal contents and normalized to total protein/sample. n=5/group. *p<.05, ****p<.0001. Error bars in bar plots represent SEM.

Following these observations, we next sought to examine whether gut bacteria and microbial signaling molecules showed long-lasting changes after recovery. First, we found that there were no significant differences in cecal SCFA levels between VEH- and DSS-treated mice at P110 (Figure 6D). Consistent with these results, we found that many of the differentially abundant SCFA-producing taxa identified to be differentially present at P71 such as *Eubacterium* coprostanoligenes group and *Roseburia* were no longer significantly different between treatments. In addition, there were fewer significantly different taxa identified at P110 (Figure 6E) compared to the P71 (Supplementary Statistics Table, Supplemental Figure 3A) acute timepoint, indicating that the microbiome composition shifted towards recovery. Of the taxa that remained differentially abundant, *Eubacterium* ventriosum group ($p_{females}$ < .0001) is a known SCFA-producing taxa (Figure 6E). Second, we measured GUS activity from cecal contents at this timepoint and found that, consistent with a shift towards recovery, GUS activity was no longer depleted in DSS-treated animals (Figure 6F). Ultimately, these findings support the notion that early life inflammation causes acute changes to the microbiome and microbial signaling molecules, some of which may equilibrate in absence of further inflammation in adulthood.

Early-life intestinal inflammation disrupts microglial morphology and brain connectivity in both sexes

SCFAs have been shown to alter microglial morphology and function (Erny et al., 2015). We therefore examined changes in microglial activation state in several brain regions. Using MicrogliaMorphology and MicrogliaMorphologyR (Kim et al., 2024a), we measured 27 morphological features from 12,318 microglia in the dorsal hippocampus (average of 513 per mouse) (Figure 7), 5,971 microglia in the hypothalamus (average of 426 per mouse) and 8,482 microglia in the cortex (average of 446 per mouse) (Supplemental Figure 4).We identified four clusters of different morphologies (Figure 7A, Supplemental Figure 4D) including microglia showing ameboid, ramified, rod-like and hypertrophic characteristics. Within the dorsal hippocampus there was a significant treatment by cluster interaction within each sex (Supplemental Table 1). Sidak corrected posthoc tests identified a significant decrease in ramified microglia in DSS-treated females (Figure 7B). In males there was a significant increase in hypertrophic microglia in the DSS-treated males. There were no significant differences in hypothalamic or cortical microglia between treatments within either sex (Supplemental Figure 4G, H). We further examined expression of cytokine genes and several immune receptors in brain tissue of DSS and VEH treated mice (Supplemental Figure 5). There were no significant differences between treatments within either sex, indicating that the sex-specific impacts of early life DSS treatment on microglia were not solely driven by neuroinflammation.



932

933 **Figure 7. Long-Term Microglial Morphology and Extraneurite Microstructure Changes**
934 **Following Early-Life DSS.** *A*. Clusters were assigned to morphology descriptions based on
935 relationship to individual metrics (see supplemental Figure 4). *B*. Example images from dorsal
936 hippocampus of female (P110) and male (P72 and P110) vehicle and DSS treated mice reveals
937 sex-specific changes in microglial morphology. Top panel is IBA1 staining. Middle panel is the
938 overlay with individual cell morphology clusters and the bottom panel is the individual cell
939 labels for each cluster. All scale bars are 50 µm. *B.* Quantification of the percentage of microglia
940 within each cluster between treatment conditions for females and males. DSS significantly
941 decreased the proportion of ramified microglia in females and increased hypertrophic microglia
942 in males. n=4-8/group *C.* Orientation dispersion index (ODI) was calculated for the bilateral
943 hippocampus across all samples. Data points are mean ODI values from each sample. Both males
944 and females had significant increases in ODI in the DSS treatment when compared to treatment
945 with the vehicle alone. n= 25-28/group * = $p < .05$, *** = $p < .001$.

946

Clinical-translational quantitative neuroimaging reveals extraneuritic hippocampal microstructural changes following early life inflammation in both sexes

We performed ex-vivo multicompartment (MC) diffusion MRI and fit it to the neurite orientation and dispersion index (NODDI) model to assess and compare microstructural changes across biologically relevant regions (hippocampus, amygdala, striatum, thalamus, hypothalamus, frontal association cortex) between the VEH- and DSS-treated mice. MC diffusion MRI enables non-invasive characterization of neuronal cytoarchitecture at the mesoscale (1- 100µm). Specifically, NODDI diffusion MRI permits non-invasive quantification of neuronal microstructure by measuring neurite density and cellular and morphometric changes occurring in the extra-neuronal space. In our imaging experiments, the mean orientation dispersion index (ODI, extra-neurite) and mean neurite density index (NDI, intra-neurite) values were tested using a 2x2 ANOVA considering the effects of treatment and sex. For ODI, a significant main effect of treatment was identified in the hippocampus (FDR-adjusted p = .0002, partial η^2 = .1560) (Figure 7D). Post-hoc testing identified that both males and females had a significant increase in their ODI value when treated with DSS compared to VEH (males: Fisher's LSD p = .0001; females: Fisher's LSD p = .0269). Additionally, a significant main effect of treatment was found in the thalamus (FDR-adjusted p = .0095, partial η^2 = .0822) (Supplemental Figure 6). Post-hoc testing indicated that females had a significant increase in their ODI value when treated with DSS compared to VEH, but that the increase in males did not reach significance (males: Fisher's LSD p = .2353; females: Fisher's LSD p = .0023). No significant treatment by sex interactions were identified in either the thalamus or hippocampus. No significant treatment or treatment by sex interaction effects were found in the frontal association cortex, amygdala, striatum, and hypothalamus. Furthermore, for NDI, no significant effects were identified in any of the regions of interest. Supplemental Table 1 contains the full findings for all regions tested.

Early-life intestinal inflammation specifically during adolescence decreases seminal vesicle weight

To examine whether the developmental timing of one DSS treatment is sufficient to induce impairments in male sex organ development, we treated male mice with DSS for 5 days either at weaning (1xDSS Weaning) or during adolescence (1xDSS Adolescence) and collected seminal vesicles at P71 (Figure 8). We found that DSS treatment produced significant decreases in body weight (treatment x day interaction $F(46, 318) = 15.111$, $p<.0001$) following DSS treatment in both groups (Figure 8 and Supplemental Table S1 and S2). DSS treatment during adolescence significantly decreased seminal vesicle weights, highlighting this developmental period as specifically sensitive to inflammatory effects on endocrine function ($F(2, 12) =7.514$, $p=.009$, $p=.0075$). Conversely, DSS treatment during weaning did not alter seminal vesicle weight at P71 ($p=.7565$). Furthermore, there was no difference in testes weight between treatments $F(2, 11) =.575$, $p =.5788$.


A
Vehicle
WATER
P21
P71
1xDSS Weaning
5 days
DSS
WATER
P21 P26
P71
1xDSS Adolescence
5 days
WATER
DSS
WATER
P21
P43 P48
P71
B
Vehicle
DSS Weaning (P21-P26)
1x DSS Adolescence (P43-P48)
% Weight Change From Baseline
Postnatal Day
P21
P26
P43
P48
P71
C
Seminal Vesicles
Seminal Vesicles (% Body Weight)
VEH
1x DSS Weaning (P21-P26)
1x DSS Adolescence (P43-P48)
D
Testes
Testes (% Body Weight)
VEH
1x DSS Weaning (P21-P26)
1x DSS Adolescence (P43-P48)

986

Figure 8. DSS Treatment During Adolescence Decreases Seminal Vesicle Weight. *A*. Male mice were treated with a single puse of DSS at either weaning (P21-26) or adolescence (P43-48) and were euthanized on P71. *B*. Body weight decreases following DSS treatment for the weaning group at P28-33 and following DSS treatment for the adolescent group beginning on P50 through the remainder of the experiment. *p<0.05 Sidak corrected posthoc tests. *C*. Seminal vesicle weights were significantly lower in the adolescent DSS treatment group compared to vehicle controls. *D*. Testes weights were not significantly different across treatments. n=4/group. Each graph bar and error bar represent the mean ± SEM. **p*<.05.

Discussion

The incidence of IBD is high and increasing, especially in early life (Benchimol et al., 2017, 2014; Ng et al., 2017)., and the disease is particularly challenging when it develops in children. Delay in the onset and progression through puberty is common in this population, and can result in reduced adult height and sexual immaturity (Gupta et al., 2020). In this study, we assessed the microbiome, intestinal, endocrine, brain, and behavioral effects of repeated DSS-induced gut inflammation in early life by developing a novel model of juvenile IBD. While early life gut inflammation did not impair the majority of the adult rodent behavioral repertoire, we identified a unique deficit in preference for female urine in DSS-treated male mice. These deficits in mate-seeking behavior corresponded to a decrease in seminal vesicle size, blunted circulating levels of androgen hormones and SCFAs, an altered gut microbiota, and altered hormone-modifying enzyme activity. Microglia were altered in the hippocampus, indicating hippocampal dysfunction may contribute to reproductive behavioral deficits in males (Kight and McCarthy, 2020).

In our model, DSS significantly decreased seminal vesicle weight (Figure 4A), circulating sex hormone levels (Figure 4D-E), and impaired male-specific preference for female urine (Figure 3C) – a key aspect of mate-seeking behavior in rodents (Keller et al., 2008; Malkesman et al., 2010). These differences were not driven by impaired olfactory discrimination, as both sexes and treatments performed normally on the olfactory habituation-dishabituation paradigm (Figure 3D-E). In both adolescent males and females with IBD, puberty onset is often delayed and progression through puberty is often prolonged, especially in patients with disease relapses (Hildebrand et al., 1994). Furthermore, adults with IBD report increased rates of sexual dysfunction (Bel et al., 2015), and infertility in both men (Hammami and Mahadevan, 2020) and women (Zhang et al., 2021; Zhao et al., 2019). This is consistent with findings from our study, where we found that DSS-treated male mice had decreased androgen hormones (Figure 4D-E) that may have directly contributed to the decrease in seminal vesicle weight (Yamane et al., 1986). Additionally, we observed that seminal vesicles in DSS-treated male mice were often not descended fully within the abdominal cavity (data not shown), and that a single DSS treatment during adolescence was sufficient to cause a decrease in seminal vesicle size (Figure 8C). While we did not observe direct impacts on male mounting behavior, future work will be required to fully examine the impacts of early life DSS on adult male reproduction and fertility.

Research suggests that hormone supplementation could potentially alleviate symptoms of IBD (Nasser et al., 2015; Rosen et al., 2015). However, the use of hormone supplementation in adolescents with IBD is contentious and can pose substantial risks due to potential side effects

1029 such as weight gain, mood changes, sleep disruption, and increased susceptibility to infections
1030 (Bishop et al., 2014). This necessitates new, non-hormone based therapies for treating adolescent
1031 IBD. The microbiota represents a potential lever for management of IBD-mediated alterations in
1032 hormones and development. Germ-free mice are known to have changes in sex hormones and
1033 pubertal onset (Markle et al., 2013; Weger et al., 2019), suggesting that the gut microbiome
1034 regulates sex hormone levels of the host. Furthermore, sex hormones can in turn regulate the gut
1035 microbiome and gastrointestinal transit time (Rastelli et al., 2022). This bidirectional relationship
1036 develops during puberty (Korpela et al., 2021). In both sexes, puberty is marked by increasing
1037 abundance of estrogen-metabolizing Clostridia and decreasing abundance of Bacteroidia
1038 (Korpela et al., 2021). Specific gut microbiota members can also secrete β-glucuronidase and β-
1039 glucosidase enzymes that deconjugate inactivated estrogens and androgens back to their active
1040 form (Ervin et al., 2019; Patel et al., 2023). These re-activated hormones are then secreted back
1041 into the circulating blood, where they can act throughout the body. In humans, estrogen levels
1042 are strongly and significantly associated with fecal Clostridia taxa, including three genera in the
1043 Ruminococcaceae family (Flores et al., 2012). This suggests that gut microbial families such as
1044 Ruminococcaceae may directly influence levels of host sex-hormones such as estrogen.
1045 Disruption of β-glucuronidase-producing microbiota results in a reduction in circulating
1046 estrogens (Baker et al., 2017), impairing the feedback loop between sex hormone levels and gut
1047 microbiota composition. In our novel model of pediatric IBD, we report differences in the key β-
1048 glucuronidase-expressing genus *Roseburia* acutely following the final round of DSS treatment,
1049 along with several *Eubacterium* groups that are known to deconjugate estrogens (Figure 5C)
1050 (Ervin et al., 2019). The relative abundance of these taxa were positively correlated with serum
1051 testosterone and androstenedione concentrations (Figure 5E), highlighting the potential
1052 involvement of these gut microbes in regulating systemic hormone levels. In addition, we
1053 observed significant decreases in cecal β-glucuronidase activity in DSS-treated males, with
1054 activity also trending lower in DSS-treated females (Figure 5G). Subsequently, we found that
1055 after resolution of inflammation, the microbiome shifts towards recovery – with most of the
1056 alterations in microbiome composition and microbial signalling molecules resolving (Figure 6).
1057 Together, these findings suggest that future microbiota-targeted therapeutics specifically
1058 impacting hormone-regulating microbes could potentially offset the negative effects of IBD on
1059 sexual health.

1060 How changes in gut inflammation drive endocrine, brain and behavior changes is not well
1061 understood, but metabolite signalling molecules have been proposed as a potential link between
1062 all three systems (Silva et al., 2020). A number of metabolites have been implicated in IBD
1063 pathogenesis, including SCFAs, secondary bile acids (SBA) and tryptophan (Lavelle and Sokol,
1064 2020; Sinha et al., 2020). These microbiota-derived metabolic signals can cross the blood-brain
1065 barrier (Mertens et al., 2017; Mitchell et al., 2011; Wenzel et al., 2020) and are critical for
1066 normal microglial development, gene regulation and metabolism (Erny et al., 2021, 2015; Thion
1067 et al., 2017). In our study, we found more differences in SCFA/MCFA abundances at the acute
1068 timepoint in the serum of DSS mice compared to VEH than in cecal contents (Figure 5A-B).
1069 This difference could be due to SCFAs being absorbed by host cells for use as energy sources. In
1070 particular, intestinal epithelial cells utilize SCFAs (particularly butyric acid) as a main source of
1071 energy, causing the concentration of SCFAs in the blood to decrease compared to what is
1072 measured in the cecum (den Besten et al., 2013). It has also been shown that butyrate uptake by
1073 colonocytes is impaired in inflamed IBD patient tissues (Thibault et al., 2010). Thus, DSS-
1074 induced inflammation could cause decoupling of cecal and serum SCFA concentrations. The

1075 reduced levels of some SCFAs observed in our pediatric IBD model may be responsible for the
1076 abnormal microglial morphology we observed (Figure 7B-C), with potential negative impacts on
1077 microglial regulation of neural circuit formation during formative years in childhood and
1078 adolescence (Sullivan and Ciernia, 2022). While previous work has shown that DSS can increase
1079 microglial inflammatory gene expression acutely in adult animals, with males showing a stronger
1080 response than females (Caetano-Silva et al., 2024), we did not observe changes in cytokine
1081 expression in our experiments (Supplemental Figure 5). However, prior work on the impacts of
1082 SCFAs on neuroinflammation is mixed. For example, increasing dietary fiber can offset the
1083 impacts of aging on microglial gene expression (Vailati-Riboni et al., 2022); however, a high
1084 fiber diet enhanced microglial inflammatory gene expression in an adult DSS model (Caetano-
1085 Silva et al., 2024) and acetate treatment exacerbated pathology in an Alzheimer's disease mouse
1086 model (Erny et al., 2021), suggesting more work is needed to understand how SCFAs modulate
1087 microglia. We found decreases in valeric acid in both males and females treated with DSS.
1088 Valerate, a ester of valeric acid, suppressed inflammation induced microglial phagocytosis in an
1089 immortalized human microglia cell line (Wenzel et al., 2020). Consistent with these findings, we
1090 observed decreased proportions of ramified microglia in DSS-treated females (Figure 7B,
1091 indicating a decrease in homeostatic microglia. We also observed an increase in hypertrophic
1092 microglia in DSS-treated males (Figure 7B), a phenotype observed previously during
1093 neuroinflammation(Kim et al., 2024b). Together, these findings suggest that early life gut
1094 inflammation can alter metabolite signaling to the brain, influencing microglial morphology in a
1095 sex-specific manner. Future work will be needed to connect the alterations in SCFA directly to
1096 microglial morphological state shifts and functions related to behaviors during development.

1097

1098 In order to test the therapeutic efficacy of any future intervention in humans, diagnostic
1099 biomarkers and biomarkers of therapeutic response are critically needed. Herein, we
1100 demonstrated that early-life DSS treatment altered increased extra-neurite signal in NODDI
1101 within the hippocampus and thalamus, but not other brain regions. The NODDI model is has
1102 been used previously to calculate the diffusion signal specific to intra-neurite and extra-neurite
1103 compartments of the brain and is sentisitve to various neuropathological states (Barnett et al.,
1104 2019; Singh et al., 2023; Stowe et al., 2024; Yi et al., 2022). Consistent with our prior work (Yi
1105 et al., 2019), changes in the ODI signal alone are consistent with its sensitivity to microglial
1106 morphology and density (Figure 7C). Importantly, this imaging technique is being developed for
1107 use in humans (Garcia-Hernandez et al., 2022), paving the way for future studies to examine
1108 microglial changes in humans with IBD.

1109 Finally, our main behavioral battery tested mouse anxiolytic, repetitive, cognitive, social and
1110 depressive-like behavior and found no significant differences between control and DSS-treated
1111 mice (Figure 2). This is in contrast to previous findings (Salvo et al., 2020), where 5 days of DSS
1112 at weaning (P21) resulted in adult (P56+) behavioral deficits on the novel object recognition task
1113 and light-dark task. This finding is rather unique in that the majority of adult DSS models show
1114 altered anxiety and memory only during active inflammation (Emge et al., 2016) and would be
1115 consistent with our findings that after recovery behavior is largely normal. One of the major
1116 differences between our work in Salvo et al., 2020 is that we used three repeated DSS treatments.
1117 The chronic nature of the current study may have induced resiliency and a faster recovery than in
1118 a single DSS treatment. Previous work in adult mice comparing one versus repeated rounds of

DSS treatment found that acute-treated mice showed impairments in memory, repetitive, depression and anxiety like behaviors while chronically treated mice only showed deficits in repetitive behaviors (Matisz et al., 2020). The authors suggest that the lack of behavior deficits in the repeated DSS treatment group may have been due to an adaptive or tolerizing effect of repeated DSS cycles (Matisz et al., 2020). Similar findings in adult mice treated with repeated rounds of DSS found no changes in locomotion, anxiety, depression or compulsive like behaviors. However, they did find lasting alterations in social interactions (Brown et al., 2024), which we did not observe. Salvo et al. did not examine sex-specific behaviors in their model; in contrast, we have observed impacts specifically on male development. When we specifically treated adolescent mice with DSS we found impacts on seminal vesicle development (Figure 8C) similar to those observed after three rounds of DSS (Figure 4A), suggesting that DSS impacts on male sexual development are driven by impacts during adolescence. Future work is required to replicate and extend our findings to identify how timing of DSS treatment impacts reproductive health including the onset of puberty and life-long fertility.

The incidence of pediatic onset IBD disease has doubled in the last 10 years (Ashton and Beattie, 2024), and young children with IBD often have more severe disease and more frequent health visits than adults (Benchimol et al., 2011). Their illness also imposes a large emotional and financial toll on families and caregivers (Herzer et al., 2011). Developing effective treatments for adolescents with IBD holds great promise, as reducing inflammation early in the disease course may prevent long-term complications, need for surgery, and hospitalization. Our novel mouse model of pediatric onset IBD, which captures alterations in the microbiome, microbial signaling molecules and brain-behavior disruptsion, represents a unique avenue for advancing our mechanistic understanding of IBD in this key subpopulation. Our findings open the door for new treatment avenues for therapeutics targeted to adolescents with IBD, with minimal side effects and maximal benefits for growth, development, and quality of life.

Funding

Research Corporation for Science Advancement, Scialog SA-MND-2021-001 (to CT, JPY) and Scialog SA-MND-2023-028a and SA-MND-2023-035c (to AVC). Canadian Institutes of Health Research (CIHR) Project Grant (to AVC, CT), Michael Smith Foundation Health Research Scholar Award (to CT, AVC), Canada Tier 2 Research Chair, Quantitative Microbiota Biology for Health Applications (to CT), Canada Tier 2 Research Chair, Understanding Gene Expression in the Brain (to AVC), Paul Allen Distinguished Investigator Award (to CT), Johnson & Johnson WiSTEM2D Award (to CT), Brain Canada Future Leaders Award (to AVC), Research Corporation for Science Advancement Award (to AVC), UBC DMCBH pilot award (to AVC), National Sciences and Engineering Research Council of Canada (NSERC) Discovery Grant (RGPIN-2020-04895) (to TH), PEO International Peace Scholarship and World Universities Ramsay Postgraduate Scholarship (to SC). None of the funding sources influenced any aspect of the study design, data collection, analysis, interpretation or writing of the manuscript.

Acknowledgements

The authors acknowledge that the land we performed this research on is the traditional, ancestral, and unceded territory of the xwməθkwəy̓əm (Musqueam) Nation. The land it is situated on has always been a place of learning for the Musqueam people, who for millennia have passed on in their culture, history, and traditions from one generation to the next on this site. We encourage others to learn more about the native lands in which they live and work at https://native-land.ca/.

This work would not be possible without the help of numerous core facilities. In particular, the authors would like to acknowledge the staff at the Centre for Disease Modeling (CDM) at UBC, Ingrid Barta at UBC Animal Care Services (ACS) Histology, and the UBC Biofactorial High-Throughput Biology Facility, supported by the University of British Columbia Global Research Excellence Biological Resilience Initiative. Thank you to the Djavad Mowafaghian Centre for Brain Health NeuroImaging and NeuroComputation Core (NINC) for data storage and computational resources. This research was supported in part through computational resources and services provided by the Advanced Research Computing at the University of British Columbia. Additionally, we would like to thank the Kopp Lab at UBC for allowing use of their tissue processor, embedder, microtome, and slide scanner. Finally, this work received support from the BC Children's Hospital Histology Core, Dr. Andy Sham, Dr. Catherine Chan, and the team from the Gut4Health Microbiome Core Facility at the BC Children's Hospital Research Institute, Lisa Nikolai from the Chromatography Facility at the Faculty of Agricultural, Life & Environmental Sciences at the University of Alberta, and Dr. Ian Nation from Animal Pathology Services Ltd. (Canmore, Alberta). Thank you to Dr. Shelly McErlane for consultation on sex organ collection in mice. Thank you to the Centre for Disease Modeling staff and animal technicians for assistance with mouse experiments and animal care.

References

Acharya, A., Shetty, S.S., Kumari N, S., 2024. Role of gut microbiota derived short chain fatty acid metabolites in modulating female reproductive health. Human Nutrition & Metabolism 36, 200256. https://doi.org/10.1016/j.hnm.2024.200256

Akhtar, M., Chen, Y., Ma, Z., Zhang, X., Shi, D., Khan, J.A., Liu, H., 2021. Gut microbiota-derived short chain fatty acids are potential mediators in gut inflammation. Anim Nutr 8, 350–360. https://doi.org/10.1016/j.aninu.2021.11.005

Alatab, S., Sepanlou, S.G., Ikuta, K., Vahedi, H., Bisignano, C., Safiri, S., Sadeghi, A., Nixon, M.R., Abdoli, A., Abolhassani, H., Alipour, V., Almadi, M.A.H., Almasi-Hashiani, A., Anushiravani, A., Arabloo, J., Atique, S., Awasthi, A., Badawi, A., Baig, A.A.A., Bhala, N., Bijani, A., Biondi, A., Borzì, A.M., Burke, K.E., Carvalho, F., Daryani, A., Dubey, M., Eftekhari, A., Fernandes, E., Fernandes, J.C., Fischer, F., Haj-Mirzaian, Arvin, Haj-Mirzaian, Arya, Hasanzadeh, A., Hashemian, M., Hay, S.I., Hoang, C.L., Househ, M., Ilesanmi, O.S., Balalami, N.J., James, S.L., Kengne, A.P., Malekzadeh, M.M., Merat, S., Meretoja, T.J., Mestrovic, T., Mirrakhimov, E.M., Mirzaei, H., Mohammad, K.A., Mokdad, A.H., Monasta, L., Negoi, I., Nguyen, T.H., Nguyen, C.T., Pourshams, A., Poustchi, H., Rabiee, M., Rabiee, N., Ramezanzadeh, K., Rawaf, D.L., Rawaf, S., Rezaei, N., Robinson, S.R., Ronfani, L., Saxena, S., Sepehrimanesh, M., Shaikh, M.A., Sharafi, Z., Sharif, M., Siabani, S., Sima, A.R., Singh, J.A., Soheili, A., Sotoudehmanesh, R., Suleria, H.A.R., Tesfay, B.E., Tran, B., Tsoi, D., Vacante, M., Wondmieneh, A.B., Zarghi, A., Zhang, Z.-J.,

Dirac, M., Malekzadeh, R., Naghavi, M., 2020. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet Gastroenterology & Hepatology 5, 17–30. https://doi.org/10.1016/S2468-1253(19)30333-4

Alexander, D.C., Hubbard, P.L., Hall, M.G., Moore, E.A., Ptito, M., Parker, G.J.M., Dyrby, T.B., 2010. Orientationally invariant indices of axon diameter and density from diffusion MRI. Neuroimage 52, 1374–1389. https://doi.org/10.1016/j.neuroimage.2010.05.043

Amann, R.I., Binder, B.J., Olson, R.J., Chisholm, S.W., Devereux, R., Stahl, D.A., 1990. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. Appl Environ Microbiol 56, 1919–1925. https://doi.org/10.1128/aem.56.6.1919-1925.1990

Ananthakrishnan, A.N., 2013. Environmental Risk Factors for Inflammatory Bowel Disease. Gastroenterol Hepatol (N Y) 9, 367–374.

Andrews, S., 2010. FastQC: A Quality Control tool for High Throughput Sequence Data [WWW Document]. FASTQC: A Quality Control tool for High Throughput Sequence Data. URL https://www.bioinformatics.babraham.ac.uk/projects/fastqc/ (accessed 5.15.24).

Arganda-Carreras, I., Fernández-González, R., Muñoz-Barrutia, A., Ortiz-De-Solorzano, C., 2010. 3D reconstruction of histological sections: Application to mammary gland tissue. Microscopy Research and Technique 73, 1019–1029. https://doi.org/10.1002/jemt.20829

Ashton, J.J., Beattie, R.M., 2024. Inflammatory bowel disease: recent developments. Arch Dis Child 109, 370–376. https://doi.org/10.1136/archdischild-2023-325668

Attree, E.A., Dancey, C.P., Keeling, D., Wilson, C., 2003. Cognitive Function in People With Chronic Illness: Inflammatory Bowel Disease and Irritable Bowel Syndrome. Applied Neuropsychology 10, 96–104. https://doi.org/10.1207/S15324826AN1002_05

Azooz, O.G., Farthing, M.J.G., Savage, M.O., Ballinger, A.B., 2001. Delayed puberty and response to testosterone in a rat model of colitis. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 281, R1483–R1491. https://doi.org/10.1152/ajpregu.2001.281.5.R1483

Baker, J.M., Al-Nakkash, L., Herbst-Kralovetz, M.M., 2017. Estrogen–gut microbiome axis: Physiological and clinical implications. Maturitas 103, 45–53. https://doi.org/10.1016/j.maturitas.2017.06.025

Ballinger, A.B., Savage, M.O., Sanderson, I.R., 2003. Delayed Puberty Associated with Inflammatory Bowel Disease. Pediatr Res 53, 205–210. https://doi.org/10.1203/01.PDR.0000047510.65483.C9

Banfi, D., Moro, E., Bosi, A., Bistoletti, M., Cerantola, S., Crema, F., Maggi, F., Giron, M.C., Giaroni, C., Baj, A., 2021. Impact of Microbial Metabolites on Microbiota–Gut–Brain Axis in Inflammatory Bowel Disease. Int J Mol Sci 22, 1623. https://doi.org/10.3390/ijms22041623

Bao, C.H., Liu, P., Liu, H.R., Wu, L.Y., Shi, Y., Chen, W.F., Qin, W., Lu, Y., Zhang, J.Y., Jin, X.M., Wang, X.M., Zhao, J.M., Liu, X.M., Tian, J., Wu, H.G., 2015. Alterations in brain grey matter structures in patients with Crohn's disease and their correlation with psychological distress. Journal of Crohn's and Colitis. https://doi.org/10.1093/ecco-jcc/jjv057

1248 Bayless, D.W., Davis, C.-H.O., Yang, R., Wei, Y., de Andrade Carvalho, V.M., Knoedler, J.R., Yang,
1249 T., Livingston, O., Lomvardas, A., Martins, G.J., Vicente, A.M., Ding, J.B., Luo, L., Shah,
1250 N.M., 2023. A neural circuit for male sexual behavior and reward. Cell 186, 3862-
1251 3881.e28. https://doi.org/10.1016/j.cell.2023.07.021
1252 Bel, L.G.J., Vollebregt, A.M., Van der Meulen-de Jong, A.E., Fidder, H.H., Ten Hove, W.R., Vliet-
1253 Vlieland, C.W., Ter Kuile, M.M., de Groot, H.E., Both, S., 2015. Sexual Dysfunctions in
1254 Men and Women with Inflammatory Bowel Disease: The Influence of IBD-Related
1255 Clinical Factors and Depression on Sexual Function. J Sex Med 12, 1557–1567.
1256 https://doi.org/10.1111/jsm.12913
1257 Benchimol, E.I., Bernstein, C.N., Bitton, A., Carroll, M.W., Singh, H., Otley, A.R., Vutcovici, M., El-
1258 Matary, W., Nguyen, G.C., Griffiths, A.M., Mack, D.R., Jacobson, K., Mojaverian, N.,
1259 Tanyingoh, D., Cui, Y., Nugent, Z.J., Coulombe, J., Targownik, L.E., Jones, J.L., Leddin, D.,
1260 Murthy, S.K., Kaplan, G.G., 2017. Trends in epidemiology of pediatric inflammatory
1261 bowel disease in Canada: Distributed network analysis of multiple population-based
1262 provincial health administrative databases. American Journal of Gastroenterology 112,
1263 1120–1134. https://doi.org/10.1038/ajg.2017.97
1264 Benchimol, E.I., Manuel, D.G., Guttmann, A., Nguyen, G.C., Mojaverian, N., Quach, P., Mack,
1265 D.R., 2014. Changing age demographics of inflammatory bowel disease in Ontario,
1266 Canada: A population-based cohort study of epidemiology trends. Inflammatory Bowel
1267 Diseases. https://doi.org/10.1097/MIB.0000000000000103
1268 Benchimol, E.I., To, T., Griffiths, A.M., Rabeneck, L., Guttmann, A., 2011. Outcomes of pediatric
1269 inflammatory bowel disease: Socioeconomic status disparity in a universal-access
1270 healthcare system. Journal of Pediatrics 158.
1271 https://doi.org/10.1016/j.jpeds.2010.11.039
1272 Bishop, J., Lemberg, D., Day, A., 2014. Managing inflammatory bowel disease in adolescent
1273 patients. Adolesc Health Med Ther 5, 1–13. https://doi.org/10.2147/AHMT.S37956
1274 Bolger, A.M., Lohse, M., Usadel, B., 2014. Trimmomatic: a flexible trimmer for Illumina
1275 sequence data. Bioinformatics 30, 2114–2120.
1276 https://doi.org/10.1093/bioinformatics/btu170
1277 Bolyen, E., Rideout, J.R., Dillon, M.R., Bokulich, N.A., Abnet, C.C., Al-Ghalith, G.A., Alexander, H.,
1278 Alm, E.J., Arumugam, M., Asnicar, F., Bai, Y., Bisanz, J.E., Bittinger, K., Brejnrod, A.,
1279 Brislawn, C.J., Brown, C.T., Callahan, B.J., Caraballo-Rodríguez, A.M., Chase, J., Cope,
1280 E.K., Da Silva, R., Diener, C., Dorrestein, P.C., Douglas, G.M., Durall, D.M., Duvallet, C.,
1281 Edwardson, C.F., Ernst, M., Estaki, M., Fouquier, J., Gauglitz, J.M., Gibbons, S.M., Gibson,
1282 D.L., Gonzalez, A., Gorlick, K., Guo, J., Hillmann, B., Holmes, S., Holste, H., Huttenhower,
1283 C., Huttley, G.A., Janssen, S., Jarmusch, A.K., Jiang, L., Kaehler, B.D., Kang, K.B., Keefe,
1284 C.R., Keim, P., Kelley, S.T., Knights, D., Koester, I., Kosciolek, T., Kreps, J., Langille, M.G.I.,
1285 Lee, J., Ley, R., Liu, Y.-X., Loftfield, E., Lozupone, C., Maher, M., Marotz, C., Martin, B.D.,
1286 McDonald, D., McIver, L.J., Melnik, A.V., Metcalf, J.L., Morgan, S.C., Morton, J.T.,
1287 Naimey, A.T., Navas-Molina, J.A., Nothias, L.F., Orchanian, S.B., Pearson, T., Peoples, S.L.,
1288 Petras, D., Preuss, M.L., Pruesse, E., Rasmussen, L.B., Rivers, A., Robeson, M.S.,
1289 Rosenthal, P., Segata, N., Shaffer, M., Shiffer, A., Sinha, R., Song, S.J., Spear, J.R.,
1290 Swafford, A.D., Thompson, L.R., Torres, P.J., Trinh, P., Tripathi, A., Turnbaugh, P.J., Ul-
1291 Hasan, S., van der Hooft, J.J.J., Vargas, F., Vázquez-Baeza, Y., Vogtmann, E., von Hippel,

M., Walters, W., Wan, Y., Wang, M., Warren, J., Weber, K.C., Williamson, C.H.D., Willis, A.D., Xu, Z.Z., Zaneveld, J.R., Zhang, Y., Zhu, Q., Knight, R., Caporaso, J.G., 2019. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol 37, 852–857. https://doi.org/10.1038/s41587-019-0209-9

Brain, C.E., Savage, M.O., 1994. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 8, 83–100. https://doi.org/10.1016/s0950-3528(06)80020-5

Brooks, M.E., Kristensen, K., Benthem, K.J. van, Magnusson, A., Berg, C.W., Nielsen, A., Skaug, H.J., Mächler, M., Bolker, B.M., 2017. glmmTMB Balances Speed and Flexibility Among Packages for Zero-inflated Generalized Linear Mixed Modeling. The R Journal 9, 378–400.

Brown, D.G., Murphy, M., Cadeddu, R., Bell, R., Weis, A., Chiaro, T., Klag, K., Morgan, J., Coon, H., Stephens, W.Z., Bortolato, M., Round, J.L., 2024. Colitis reduces active social engagement in mice and is ameliorated by supplementation with human microbiota members. Nat Commun 15, 2769. https://doi.org/10.1038/s41467-024-46733-7

Buchfink, B., Xie, C., Huson, D.H., 2015. Fast and sensitive protein alignment using DIAMOND. Nat Methods 12, 59–60. https://doi.org/10.1038/nmeth.3176

Caetano-Silva, M.E., Rund, L., Vailati-Riboni, M., Matt, S., Soto-Diaz, K., Beever, J., Allen, J.M., Woods, J.A., Steelman, A.J., Johnson, R.W., 2024. The emergence of inflammatory microglia during gut inflammation is not affected by FFAR2 expression in intestinal epithelial cells or peripheral myeloid cells. Brain Behav Immun 118, 423–436. https://doi.org/10.1016/j.bbi.2024.03.016

Callahan, B.J., McMurdie, P.J., Rosen, M.J., Han, A.W., Johnson, A.J.A., Holmes, S.P., 2016. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods 13, 581–583. https://doi.org/10.1038/nmeth.3869

Can, A., Dao, D.T., Arad, M., Terrillion, C.E., Piantadosi, S.C., Gould, T.D., 2011. The Mouse Forced Swim Test. JoVE 3638. https://doi.org/10.3791/3638

Cao, Y., Dong, Q., Wang, D., Zhang, P., Liu, Y., Niu, C., 2022. microbiomeMarker: an R/Bioconductor package for microbiome marker identification and visualization. Bioinformatics 38, 4027–4029. https://doi.org/10.1093/bioinformatics/btac438

Chassaing, B., Aitken, J.D., Malleshappa, M., Vijay-Kumar, M., 2014. Dextran Sulfate Sodium (DSS)-Induced Colitis in Mice. Curr Protoc Immunol 104, Unit-15.25. https://doi.org/10.1002/0471142735.im1525s104

Chen, D., Zhou, C., Luo, Q., Chen, C., Liu, G., 2024. A Mendelian randomization study on causal effects of inflammatory bowel disease on the risk of erectile dysfunction. Sci Rep 14, 2137. https://doi.org/10.1038/s41598-024-52712-1

Colldén, H., Landin, A., Wallenius, V., Elebring, E., Fändriks, L., Nilsson, M.E., Ryberg, H., Poutanen, M., Sjögren, K., Vandenput, L., Ohlsson, C., 2019. The gut microbiota is a major regulator of androgen metabolism in intestinal contents. American Journal of Physiology-Endocrinology and Metabolism 317, E1182–E1192. https://doi.org/10.1152/ajpendo.00338.2019

Cotton, S., Clayton, C.A., Tropini, C., 2023. Microbial endocrinology: the mechanisms by which the microbiota influences host sex steroids. Trends in Microbiology 31, 1131–1142. https://doi.org/10.1016/j.tim.2023.03.010

Cryan, J.F., Dinan, T.G., 2012. Mind-altering microorganisms: The impact of the gut microbiota on brain and behaviour. Nature Reviews Neuroscience 13, 701–712. https://doi.org/10.1038/nrn3346

Däbritz, J., Gerner, P., Enninger, A., Claßen, M., Radke, M., 2017. Inflammatory Bowel Disease in Childhood and Adolescence. Dtsch Arztebl Int 114, 331–338. https://doi.org/10.3238/arztebl.2017.0331

De Wolfe, T.J., Wright, E.S., 2023. Multi-factorial examination of amplicon sequencing workflows from sample preparation to bioinformatic analysis. BMC Microbiol 23, 107. https://doi.org/10.1186/s12866-023-02851-8

Deboer, M.D., Li, Y., 2011. Puberty Is Delayed in Male Mice With Dextran Sodium Sulfate Colitis Out of Proportion to Changes in Food Intake, Body Weight, and Serum Levels of Leptin. Pediatr Res 69, 34–39. https://doi.org/10.1203/PDR.0b013e3181ffee6c

DeBoer, M.D., Li, Y., Cohn, S., 2010. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol 45, 277–284. https://doi.org/10.1007/s00535-009-0192-x

den Besten, G., van Eunen, K., Groen, A.K., Venema, K., Reijngoud, D.-J., Bakker, B.M., 2013. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. Journal of Lipid Research 54, 2325–2340. https://doi.org/10.1194/jlr.R036012

Dixon, P., 2003. VEGAN, a package of R functions for community ecology. Journal of Vegetation Science 14, 927–930. https://doi.org/10.1111/j.1654-1103.2003.tb02228.x

Effendi, R.M.R.A., Anshory, M., Kalim, H., Dwiyana, R.F., Suwarsa, O., Pardo, L.M., Nijsten, T.E.C., Thio, H.B., 2022. Akkermansia muciniphila and Faecalibacterium prausnitzii in Immune-Related Diseases. Microorganisms 10, 2382. https://doi.org/10.3390/microorganisms10122382

Eichele, D.D., Kharbanda, K.K., 2017. Dextran sodium sulfate colitis murine model: An indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J Gastroenterol 23, 6016–6029. https://doi.org/10.3748/wjg.v23.i33.6016

Emge, J.R., Huynh, K., Miller, E.N., Kaur, M., Reardon, C., Barrett, K.E., Gareau, M.G., 2016. Modulation of the microbiota-gut-brain axis by probiotics in a murine model of inflammatory bowel disease. American Journal of Physiology-Gastrointestinal and Liver Physiology 310, G989–G998. https://doi.org/10.1152/ajpgi.00086.2016

Erny, D., De Angelis, A.L.H., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., Schwierzeck, V., Utermöhlen, O., Chun, E., Garrett, W.S., Mccoy, K.D., Diefenbach, A., Staeheli, P., Stecher, B., Amit, I., Prinz, M., 2015. Host microbiota constantly control maturation and function of microglia in the CNS. Nature Neuroscience 18, 965–977. https://doi.org/10.1038/nn.4030

Erny, D., Dokalis, N., Mezö, C., Castoldi, A., Mossad, O., Staszewski, O., Frosch, M., Villa, M., Fuchs, V., Mayer, A., Neuber, J., Sosat, J., Tholen, S., Schilling, O., Vlachos, A., Blank, T., Agüero, M.G. de, Macpherson, A.J., Pearce, E.J., Prinz, M., 2021. Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Cell Metabolism 33, 2260-2276.e7. https://doi.org/10.1016/j.cmet.2021.10.010

1379 Ervin, S.M., Li, H., Lim, L., Roberts, L.R., Liang, X., Mani, S., Redinbo, M.R., 2019. Gut microbial β-
1380 glucuronidases reactivate estrogens as components of the estrobolome that reactivate
1381 estrogens. Journal of Biological Chemistry 294, 18586–18599.
1382 https://doi.org/10.1074/jbc.RA119.010950
1383 Ewels, P., Magnusson, M., Lundin, S., Käller, M., 2016. MultiQC: summarize analysis results for
1384 multiple tools and samples in a single report. Bioinformatics 32, 3047–3048.
1385 https://doi.org/10.1093/bioinformatics/btw354
1386 Flores, R., Shi, J., Fuhrman, B., Xu, X., Veenstra, T.D., Gail, M.H., Gajer, P., Ravel, J., Goedert, J.J.,
1387 2012. Fecal microbial determinants of fecal and systemic estrogens and estrogen
1388 metabolites: a cross-sectional study. Journal of Translational Medicine 10, 253.
1389 https://doi.org/10.1186/1479-5876-10-253
1390 Fusco, W., Lorenzo, M.B., Cintoni, M., Porcari, S., Rinninella, E., Kaitsas, F., Lener, E., Mele, M.C.,
1391 Gasbarrini, A., Collado, M.C., Cammarota, G., Ianiro, G., 2023. Short-Chain Fatty-Acid-
1392 Producing Bacteria: Key Components of the Human Gut Microbiota. Nutrients 15, 2211.
1393 https://doi.org/10.3390/nu15092211
1394 Gaidos, J.K.J., Naik, K., Dave, J., Yao, M., Hou, J.K., Cipher, D.J., Smith, A.D., Feagins, L.A., 2020.
1395 High Prevalence of Male Sexual Dysfunction in a Prospective Multicenter VA
1396 Inflammatory Bowel Disease Population. Crohns Colitis 360 2, otaa004.
1397 https://doi.org/10.1093/crocol/otaa004
1398 Gampierakis, I.-A., Koutmani, Y., Semitekolou, M., Morianos, I., Polissidis, A., Katsouda, A.,
1399 Charalampopoulos, I., Xanthou, G., Gravanis, A., Karalis, K.P., 2021. Hippocampal neural
1400 stem cells and microglia response to experimental inflammatory bowel disease (IBD).
1401 Mol Psychiatry 26, 1248–1263. https://doi.org/10.1038/s41380-020-0651-6
1402 Garcia-Hernandez, R., Cerdán Cerdá, A., Trouve Carpena, A., Drakesmith, M., Koller, K., Jones,
1403 D.K., Canals, S., De Santis, S., 2022. Mapping microglia and astrocyte activation in vivo
1404 using diffusion MRI. Science Advances 8, eabq2923.
1405 https://doi.org/10.1126/sciadv.abq2923
1406 Gu, Z., Eils, R., Schlesner, M., 2016. Complex heatmaps reveal patterns and correlations in
1407 multidimensional genomic data. Bioinformatics 32, 2847–2849.
1408 https://doi.org/10.1093/bioinformatics/btw313
1409 Günther, C., Rothhammer, V., Karow, M., Neurath, M., Winner, B., 2021. The Gut-Brain Axis in
1410 Inflammatory Bowel Disease—Current and Future Perspectives. Int J Mol Sci 22, 8870.
1411 https://doi.org/10.3390/ijms22168870
1412 Gupta, N., Lustig, R.H., Andrews, H., Sylvester, F., Keljo, D., Goyal, A., Gokhale, R., Patel, A.S.,
1413 Guthery, S., Leu, C.-S., 2020. Introduction to and Screening Visit Results of the
1414 Multicenter Pediatric Crohn's Disease Growth Study. Inflammatory Bowel Diseases 26,
1415 1945–1950. https://doi.org/10.1093/ibd/izaa023
1416 Hadley, W., 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.
1417 Hamden, J.E., Gray, K.M., Salehzadeh, M., Kachkovski, G.V., Forys, B.J., Ma, C., Austin, S.H.,
1418 Soma, K.K., 2021. Steroid profiling of glucocorticoids in microdissected mouse brain
1419 across development. Developmental Neurobiology 81, 189–206.
1420 https://doi.org/10.1002/dneu.22808
1421 Hamden, J.E., Salehzadeh, M., Jalabert, C., O'Leary, T.P., Snyder, J.S., Gomez-Sanchez, C.E.,
1422 Soma, K.K., 2019. Measurement of 11-dehydrocorticosterone in mice, rats and

1423 songbirds: Effects of age, sex and stress. General and Comparative Endocrinology 281,
1424 173–182. https://doi.org/10.1016/j.ygcen.2019.05.018
1425 Hammami, M.B., Mahadevan, U., 2020. Men With Inflammatory Bowel Disease: Sexual
1426 Function, Fertility, Medication Safety, and Prostate Cancer. Am J Gastroenterol 115,
1427 526–534. https://doi.org/10.14309/ajg.0000000000000515
1428 Han, S., Treuren, W.V., Fischer, C.R., Merrill, B.D., DeFelice, B.C., Sanchez, J.M., Higginbottom,
1429 S.K., Guthrie, L., Fall, L.A., Dodd, D., Fischbach, M.A., Sonnenburg, J.L., 2021. A
1430 metabolomics pipeline for mechanistic interrogation of the gut microbiome. Nature 595,
1431 415. https://doi.org/10.1038/s41586-021-03707-9
1432 Handelsman, D.J., Ly, L.P., 2019. An Accurate Substitution Method To Minimize Left Censoring
1433 Bias in Serum Steroid Measurements. Endocrinology 160, 2395–2400.
1434 https://doi.org/10.1210/en.2019-00340
1435 Harms, R.L., Fritz, F.J., Tobisch, A., Goebel, R., Roebroeck, A., 2017. Robust and fast nonlinear
1436 optimization of diffusion MRI microstructure models. Neuroimage 155, 82–96.
1437 https://doi.org/10.1016/j.neuroimage.2017.04.064
1438 He, S., Li, H., Yu, Z., Zhang, F., Liang, S., Liu, H., Chen, H., Lü, M., 2021. The Gut Microbiome and
1439 Sex Hormone-Related Diseases. Frontiers in Microbiology 12.
1440 Herzer, M., Denson, L.A., Baldassano, R.N., Hommel, K.A., 2011. Patient and parent
1441 psychosocial factors associated with health-related quality of life in pediatric
1442 inflammatory bowel disease. Journal of Pediatric Gastroenterology and Nutrition 52,
1443 295–299. https://doi.org/10.1097/MPG.0b013e3181f5714e
1444 Hildebrand, H., Karlberg, J., Kristiansson, B., 1994. Longitudinal growth in children and
1445 adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 18, 165–173.
1446 https://doi.org/10.1097/00005176-199402000-00008
1447 Hodgkinson, K., El Abbar, F., Dobranowski, P., Manoogian, J., Butcher, J., Figeys, D., Mack, D.,
1448 Stintzi, A., 2023. Butyrate's role in human health and the current progress towards its
1449 clinical application to treat gastrointestinal disease. Clinical Nutrition 42, 61–75.
1450 https://doi.org/10.1016/j.clnu.2022.10.024
1451 Hou, J., Dodd, K., Nair, V.A., Rajan, S., Beniwal-Patel, P., Saha, S., Prabhakaran, V., 2020.
1452 Alterations in brain white matter microstructural properties in patients with Crohn's
1453 disease in remission. Scientific Reports. https://doi.org/10.1038/s41598-020-59098-w
1454 Huerta-Cepas, J., Szklarczyk, D., Forslund, K., Cook, H., Heller, D., Walter, M.C., Rattei, T.,
1455 Mende, D.R., Sunagawa, S., Kuhn, M., Jensen, L.J., von Mering, C., Bork, P., 2016.
1456 eggNOG 4.5: a hierarchical orthology framework with improved functional annotations
1457 for eukaryotic, prokaryotic and viral sequences. Nucleic Acids Research 44, D286–D293.
1458 https://doi.org/10.1093/nar/gkv1248
1459 Hyatt, D., Chen, G.-L., LoCascio, P.F., Land, M.L., Larimer, F.W., Hauser, L.J., 2010. Prodigal:
1460 prokaryotic gene recognition and translation initiation site identification. BMC
1461 Bioinformatics 11, 119. https://doi.org/10.1186/1471-2105-11-119
1462 Jiang, Y., Johnson, G.A., 2011. Microscopic diffusion tensor atlas of the mouse brain.
1463 NeuroImage 56, 1235–1243. https://doi.org/10.1016/j.neuroimage.2011.03.031
1464 Kanehisa, M., Goto, S., 2000. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids
1465 Research 28, 27–30. https://doi.org/10.1093/nar/28.1.27

Kaplan, G.G., Windsor, J.W., 2021. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 18, 56–66. https://doi.org/10.1038/s41575-020-00360-x

Kassambara, A., 2023. ggpubr: "ggplot2" Based Publication Ready Plots [WWW Document]. URL https://rpkgs.datanovia.com/ggpubr/

Katoh, K., Misawa, K., Kuma, K., Miyata, T., 2002. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Research 30, 3059–3066. https://doi.org/10.1093/nar/gkf436

Keller, M., Baum, M.J., Bakker, J., 2008. Olfactory Control of Sex-Recognition and Sexual Behavior in Mice, in: Hurst, J.L., Beynon, R.J., Roberts, S.C., Wyatt, T.D. (Eds.), Chemical Signals in Vertebrates 11. Springer, New York, NY, pp. 241–250. https://doi.org/10.1007/978-0-387-73945-8_23

Kight, K.E., McCarthy, M.M., 2020. Androgens and the developing hippocampus. Biol Sex Differ 11, 30. https://doi.org/10.1186/s13293-020-00307-6

Kim, J., Pavlidis, P., Ciernia, A.V., 2024a. Development of a high-throughput pipeline to characterize microglia morphological states at a single-cell resolution. eNeuro. https://doi.org/10.1523/ENEURO.0014-24.2024

Kim, J., Sullivan, O., Lee, K., Jao, J., Tamayo, J., Madany, A.M., Wong, B., Ashwood, P., Ciernia, A.V., 2024b. Repeated LPS induces training and tolerance of microglial responses across brain regions. https://doi.org/10.1101/2024.04.08.588502

Kim, K., Choe, D., Song, Y., Kang, M., Lee, S.-G., Lee, D.-H., Cho, B.-K., 2021. Engineering *Bacteroides thetaiotaomicron* to produce non-native butyrate based on a genome-scale metabolic model-guided design. Metabolic Engineering 68, 174–186. https://doi.org/10.1016/j.ymben.2021.10.005

Klaus, J., Reinshagen, M., Adler, G., Boehm, B., von Tirpitz, C., 2008. Bones and Crohn's: Estradiol deficiency in men with Crohn's disease is not associated with reduced bone mineral density. BMC Gastroenterol 8, 48. https://doi.org/10.1186/1471-230X-8-48

Kleine Bardenhorst, S., Vital, M., Karch, A., Rübsamen, N., 2022. Richness estimation in microbiome data obtained from denoising pipelines. Computational and Structural Biotechnology Journal 20, 508–520. https://doi.org/10.1016/j.csbj.2021.12.036

Korpela, K., Kallio, S., Salonen, A., Hero, M., Kukkonen, A.K., Miettinen, P.J., Savilahti, E., Kohva, E., Kariola, L., Suutela, M., Tarkkanen, A., de Vos, W.M., Raivio, T., Kuitunen, M., 2021. Gut microbiota develop towards an adult profile in a sex-specific manner during puberty. Sci Rep 11, 23297. https://doi.org/10.1038/s41598-021-02375-z

Langmead, B., Salzberg, S.L., 2012. Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357–359. https://doi.org/10.1038/nmeth.1923

Lavelle, A., Sokol, H., 2020. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology 17, 223–237. https://doi.org/10.1038/s41575-019-0258-z

Li, D., Liu, C.-M., Luo, R., Sadakane, K., Lam, T.-W., 2015. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics 31, 1674–1676. https://doi.org/10.1093/bioinformatics/btv033

Li, D., Liu, R., Wang, M., Peng, R., Fu, S., Fu, A., Le, J., Yao, Q., Yuan, T., Chi, H., Mu, X., Sun, T., Liu, H., Yan, P., Wang, S., Cheng, S., Deng, Z., Liu, Z., Wang, G., Li, Y., Liu, T., 2022. 3β-

Hydroxysteroid dehydrogenase expressed by gut microbes degrades testosterone and is linked to depression in males. Cell Host & Microbe 30, 329-339.e5. https://doi.org/10.1016/j.chom.2022.01.001

Lv, K., Fan, Y.H., Xu, L., Xu, M.S., 2017. Brain changes detected by functional magnetic resonance imaging and spectroscopy in patients with Crohn's disease. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v23.i20.3607

Machiels, K., Joossens, M., Sabino, J., De Preter, V., Arijs, I., Eeckhaut, V., Ballet, V., Claes, K., Van Immerseel, F., Verbeke, K., Ferrante, M., Verhaegen, J., Rutgeerts, P., Vermeire, S., 2014. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63, 1275–1283. https://doi.org/10.1136/gutjnl-2013-304833

Mackner, L.M., Greenley, R.N., Szigethy, E., Herzer, M., Deer, K., Hommel, K.A., 2013. Psychosocial Issues in Pediatric Inflammatory Bowel Disease: A Clinical Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 56, 449–458. https://doi.org/10.1097/MPG.0b013e3182841263

Maffei, S., Forini, F., Canale, P., Nicolini, G., Guiducci, L., 2022. Gut Microbiota and Sex Hormones: Crosstalking Players in Cardiometabolic and Cardiovascular Disease. International Journal of Molecular Sciences 23, 7154. https://doi.org/10.3390/ijms23137154

Malkesman, O., Scattoni, M.L., Paredes, D., Tragon, T., Pearson, B., Shaltiel, G., Chen, G., Crawley, J.N., Manji, H.K., 2010. The Female Urine Sniffing Test: A Novel Approach for Assessing Reward-Seeking Behavior in Rodents. Biol Psychiatry 67, 864–871. https://doi.org/10.1016/j.biopsych.2009.10.018

Mandal, S., Van Treuren, W., White, R.A., Eggesbø, M., Knight, R., Peddada, S.D., 2015. Analysis of composition of microbiomes: a novel method for studying microbial composition. Microb Ecol Health Dis 26, 27663. https://doi.org/10.3402/mehd.v26.27663

Markle, J.G.M., Frank, D.N., Mortin-Toth, S., Robertson, C.E., Feazel, L.M., Rolle-Kampczyk, U., von Bergen, M., McCoy, K.D., Macpherson, A.J., Danska, J.S., 2013. Sex Differences in the Gut Microbiome Drive Hormone-Dependent Regulation of Autoimmunity. Science 339, 1084–1088. https://doi.org/10.1126/science.1233521

Matisz, C.E., Vicentini, F.A., Hirota, S.A., Sharkey, K.A., Gruber, A.J., 2020. Behavioral adaptations in a relapsing mouse model of colitis. Physiol Behav 216, 112802. https://doi.org/10.1016/j.physbeh.2020.112802

McMurdie, P.J., Holmes, S., 2013. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. PLOS ONE 8, e61217. https://doi.org/10.1371/journal.pone.0061217

Mertens, K.L., Kalsbeek, A., Soeters, M.R., Eggink, H.M., 2017. Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. Frontiers in Neuroscience 11.

Min, S.H., Zhou, J., 2021. smplot: An R Package for Easy and Elegant Data Visualization. Front. Genet. 12. https://doi.org/10.3389/fgene.2021.802894

Mirzaei, R., Bouzari, B., Hosseini-Fard, S.R., Mazaheri, M., Ahmadyousefi, Y., Abdi, M., Jalalifar, S., Karimitabar, Z., Teimoori, A., Keyvani, H., Zamani, F., Yousefimashouf, R., Karampoor,

1554 S., 2021. Role of microbiota-derived short-chain fatty acids in nervous system disorders.
1555 Biomed Pharmacother 139, 111661. https://doi.org/10.1016/j.biopha.2021.111661
1556 Mitchell, R.W., On, N.H., Del Bigio, M.R., Miller, D.W., Hatch, G.M., 2011. Fatty acid transport
1557 protein expression in human brain and potential role in fatty acid transport across
1558 human brain microvessel endothelial cells. J Neurochem 117, 735–746.
1559 https://doi.org/10.1111/j.1471-4159.2011.07245.x
1560 Munyaka, P.M., Rabbi, M.F., Khafipour, E., Ghia, J., 2016. Acute dextran sulfate sodium (DSS)-
1561 induced colitis promotes gut microbial dysbiosis in mice. J. Basic Microbiol. 56, 986–998.
1562 https://doi.org/10.1002/jobm.201500726
1563 Naser, S.A., Sagramsingh, S.R., Naser, A.S., Thanigachalam, S., 2014. Mycobacterium avium
1564 subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel
1565 disease patients. World J Gastroenterol 20, 7403–7415.
1566 https://doi.org/10.3748/wjg.v20.i23.7403
1567 Nasser, M., Haider, A., Saad, F., Kurtz, W., Doros, G., Fijak, M., Vignozzi, L., Gooren, L., 2015.
1568 Testosterone therapy in men with Crohn's disease improves the clinical course of the
1569 disease: data from long-term observational registry study. Horm Mol Biol Clin Investig
1570 22, 111–117. https://doi.org/10.1515/hmbci-2015-0014
1571 Neuman, H., Debelius, J.W., Knight, R., Koren, O., 2015. Microbial endocrinology: the interplay
1572 between the microbiota and the endocrine system. FEMS Microbiology Reviews 39,
1573 509–521. https://doi.org/10.1093/femsre/fuu010
1574 Ng, K.M., Pannu, S., Liu, S., Burckhardt, J.C., Hughes, T., Van Treuren, W., Nguyen, J., Naqvi, K.,
1575 Nguyen, B., Clayton, C.A., Pepin, D.M., Collins, S.R., Tropini, C., 2023. Single-strain
1576 behavior predicts responses to environmental pH and osmolality in the gut microbiota.
1577 mBio 14, e00753-23. https://doi.org/10.1128/mbio.00753-23
1578 Ng, K.M., Tropini, C., 2021. Visualization of Gut Microbiota-host Interactions via Fluorescence In
1579 Situ Hybridization, Lectin Staining, and Imaging. JoVE (Journal of Visualized Experiments)
1580 e62646. https://doi.org/10.3791/62646
1581 Ng, S.C., Shi, H.Y., Hamidi, N., Underwood, F.E., Tang, W., Benchimol, E.I., Panaccione, R.,
1582 Ghosh, S., Wu, J.C.Y., Chan, F.K.L., Sung, J.J.Y., Kaplan, G.G., 2017. Worldwide incidence
1583 and prevalence of inflammatory bowel disease in the 21st century: a systematic review
1584 of population-based studies. The Lancet. https://doi.org/10.1016/S0140-
1585 6736(17)32448-0
1586 Nyuyki, K.D., Cluny, N.L., Swain, M.G., Sharkey, K.A., Pittman, Q.J., 2018. Altered brain
1587 excitability and increased anxiety in mice with experimental colitis: Consideration of
1588 hyperalgesia and sex differences. Frontiers in Behavioral Neuroscience 12, 1–11.
1589 https://doi.org/10.3389/fnbeh.2018.00058
1590 Patel, J., Chaudhary, H., Rajput, K., Parekh, B., Joshi, R., 2023. Assessment of gut microbial β-
1591 glucuronidase and β-glucosidase activity in women with polycystic ovary syndrome. Sci
1592 Rep 13, 11967. https://doi.org/10.1038/s41598-023-39168-5
1593 Paulson, J.N., Stine, O.C., Bravo, H.C., Pop, M., 2013. Differential abundance analysis for
1594 microbial marker-gene surveys. Nat Methods 10, 1200–1202.
1595 https://doi.org/10.1038/nmeth.2658

1596 Price, M.N., Dehal, P.S., Arkin, A.P., 2010. FastTree 2 – Approximately Maximum-Likelihood
1597 Trees for Large Alignments. PLOS ONE 5, e9490.
1598 https://doi.org/10.1371/journal.pone.0009490
1599 Puente-Sánchez, F., García-García, N., Tamames, J., 2020. SQMtools: automated processing and
1600 visual analysis of 'omics data with R and anvi'o. BMC Bioinformatics 21, 358.
1601 https://doi.org/10.1186/s12859-020-03703-2
1602 Quast, C., Pruesse, E., Yilmaz, P., Gerken, J., Schweer, T., Yarza, P., Peplies, J., Glöckner, F.O.,
1603 2013. The SILVA ribosomal RNA gene database project: improved data processing and
1604 web-based tools. Nucleic Acids Res 41, D590–D596.
1605 https://doi.org/10.1093/nar/gks1219
1606 R Core team, 2021. R: A language and environment for statistical computing [WWW
1607 Document]. URL https://www.r-project.org/ (accessed 4.1.23).
1608 Rastelli, D., Robinson, A., Lagomarsino, V.N., Matthews, L.T., Hassan, R., Perez, K., Dan, W., Yim,
1609 P.D., Mixer, M., Prochera, A., Shepherd, A., Sun, L., Hall, K., Ballou, S., Lembo, A., Nee, J.,
1610 Rao, M., 2022. Diminished androgen levels are linked to irritable bowel syndrome and
1611 cause bowel dysfunction in mice. J Clin Invest 132, e150789.
1612 https://doi.org/10.1172/JCI150789
1613 Robinson, M.D., McCarthy, D.J., Smyth, G.K., 2009. edgeR: a Bioconductor package for
1614 differential expression analysis of digital gene expression data. Bioinformatics 26, 139.
1615 https://doi.org/10.1093/bioinformatics/btp616
1616 Roda, G., Chien Ng, S., Kotze, P.G., Argollo, M., Panaccione, R., Spinelli, A., Kaser, A., Peyrin-
1617 Biroulet, L., Danese, S., 2020. Crohn's disease. Nat Rev Dis Primers 6, 1–19.
1618 https://doi.org/10.1038/s41572-020-0156-2
1619 Rosen, M.J., Dhawan, A., Saeed, S.A., 2015. Inflammatory Bowel Disease in Children and
1620 Adolescents. JAMA Pediatr 169, 1053–1060.
1621 https://doi.org/10.1001/jamapediatrics.2015.1982
1622 Salvo, E., Stokes, P., Keogh, C.E., Brust-Mascher, I., Hennessey, C., Knotts, T.A., Sladek, J.A.,
1623 Rude, K.M., Swedek, M., Rabasa, G., Gareau, M.G., 2020. A murine model of pediatric
1624 inflammatory bowel disease causes microbiota-gut-brain axis deficits in adulthood. Am J
1625 Physiol Gastrointest Liver Physiol 319, G361–G374.
1626 https://doi.org/10.1152/ajpgi.00177.2020
1627 Seemann, T., 2024. tseemann/barrnap.
1628 Silva, Y.P., Bernardi, A., Frozza, R.L., 2020. The Role of Short-Chain Fatty Acids From Gut
1629 Microbiota in Gut-Brain Communication. Frontiers in Endocrinology 11.
1630 https://doi.org/10.3389/fendo.2020.00025
1631 Sinha, S.R., Haileselassie, Y., Nguyen, L.P., Tropini, C., Wang, M., Becker, L.S., Sim, D., Jarr, K.,
1632 Spear, E.T., Singh, G., Namkoong, H., Bittinger, K., Fischbach, M.A., Sonnenburg, J.L.,
1633 Habtezion, A., 2020. Dysbiosis-Induced Secondary Bile Acid Deficiency Promotes
1634 Intestinal Inflammation. Cell Host Microbe 27, 659-670.e5.
1635 https://doi.org/10.1016/j.chom.2020.01.021
1636 Smith, S.M., Jenkinson, M., Woolrich, M.W., Beckmann, C.F., Behrens, T.E.J., Johansen-Berg, H.,
1637 Bannister, P.R., De Luca, M., Drobnjak, I., Flitney, D.E., Niazy, R.K., Saunders, J., Vickers,
1638 J., Zhang, Y., De Stefano, N., Brady, J.M., Matthews, P.M., 2004. Advances in functional

and structural MR image analysis and implementation as FSL. Neuroimage 23 Suppl 1, S208-219. https://doi.org/10.1016/j.neuroimage.2004.07.051

Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermúdez-Humarán, L.G., Gratadoux, J.J., Blugeon, S., Bridonneau, C., Furet, J.P., Corthier, G., Grangette, C., Vasquez, N., Pochart, P., Trugnan, G., Thomas, G., Blottière, H.M., Doré, J., Marteau, P., Seksik, P., Langella, P., 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proceedings of the National Academy of Sciences of the United States of America 105, 16731–16736. https://doi.org/10.1073/pnas.0804812105

Sroor, H.M., Hassan, A.M., Zenz, G., Valadez-Cosmes, P., Farzi, A., Holzer, P., El-Sharif, A., Gomaa, F.A.-Z.M., Kargl, J., Reichmann, F., 2019. Experimental colitis reduces microglial cell activation in the mouse brain without affecting microglial cell numbers. Sci Rep 9, 20217. https://doi.org/10.1038/s41598-019-56859-0

Stahl, M., Graef, F.A., Vallance, B.A., 2017. Mouse Models for Campylobacter jejuni Colonization and Infection, in: Butcher, J., Stintzi, A. (Eds.), Campylobacter Jejuni: Methods and Protocols. Springer, New York, NY, pp. 171–188. https://doi.org/10.1007/978-1-4939-6536-6_15

Sui, Y., Wu, J., Chen, J., 2021. The Role of Gut Microbial β-Glucuronidase in Estrogen Reactivation and Breast Cancer. Front Cell Dev Biol 9, 631552. https://doi.org/10.3389/fcell.2021.631552

Sullivan, O., Ciernia, A.V., 2022. Work hard, play hard: how sexually differentiated microglia work to shape social play and reproductive behavior. Frontiers in Behavioral Neuroscience 16.

Talley, S., Valiauga, R., Anderson, L., Cannon, A.R., Choudhry, M.A., Campbell, E.M., 2021. DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod. Journal of Neuroinflammation 18, 263. https://doi.org/10.1186/s12974-021-02317-6

Tamames, J., Puente-Sánchez, F., 2019. SqueezeMeta, A Highly Portable, Fully Automatic Metagenomic Analysis Pipeline. Front. Microbiol. 9. https://doi.org/10.3389/fmicb.2018.03349

Terstege, D.J., Oboh, D.O., Epp, J.R., 2022. FASTMAP: Open-Source Flexible Atlas Segmentation Tool for Multi-Area Processing of Biological Images. eNeuro 9, ENEURO.0325-21.2022. https://doi.org/10.1523/ENEURO.0325-21.2022

Thavamani, A., Umapathi, K.K., Khatana, J., Gulati, R., 2019. Burden of Psychiatric Disorders among Pediatric and Young Adults with Inflammatory Bowel Disease: A Population-Based Analysis. Pediatr Gastroenterol Hepatol Nutr 22, 527–535. https://doi.org/10.5223/pghn.2019.22.6.527

Thibault, R., Blachier, F., Darcy-Vrillon, B., de Coppet, P., Bourreille, A., Segain, J.-P., 2010. Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 16, 684–695. https://doi.org/10.1002/ibd.21108

Thion, M.S., Low, D., Silvin, A., Chen, J., Grisel, P., Schulte-Schrepping, J., Blecher, R., Ulas, T., Squarzoni, P., Hoeffel, G., Coulpier, F., Siopi, E., David, F.S., Scholz, C., Shihui, F., Lum, J., Amoyo, A.A., Larbi, A., Poidinger, M., Buttgereit, A., Lledo, P.-M., Greter, M., Chan, J.K.Y., Amit, I., Beyer, M., Schultze, J.L., Schlitzer, A., Pettersson, S., Ginhoux, F., Garel, S.,

1683 2017. Microbiome Influences Prenatal and Adult Microglia in a Sex-Specific Manner. Cell
1684 1–17. https://doi.org/10.1016/j.cell.2017.11.042
1685 Tigas, S., Tsatsoulis, A., 2012. Endocrine and metabolic manifestations in inflammatory bowel
1686 disease. Ann Gastroenterol 25, 37–44.
1687 Torres, P.J., Siakowska, M., Banaszewska, B., Pawelczyk, L., Duleba, A.J., Kelley, S.T., Thackray,
1688 V.G., 2018. Gut Microbial Diversity in Women With Polycystic Ovary Syndrome
1689 Correlates With Hyperandrogenism. J Clin Endocrinol Metab 103, 1502–1511.
1690 https://doi.org/10.1210/jc.2017-02153
1691 Vailati-Riboni, M., Rund, L., Caetano-Silva, M.E., Hutchinson, N.T., Wang, S.S., Soto-Díaz, K.,
1692 Woods, J.A., Steelman, A.J., Johnson, R.W., 2022. Dietary Fiber as a Counterbalance to
1693 Age-Related Microglial Cell Dysfunction. Front Nutr 9, 835824.
1694 https://doi.org/10.3389/fnut.2022.835824
1695 van Griethuysen, J.J.M., Fedorov, A., Parmar, C., Hosny, A., Aucoin, N., Narayan, V., Beets-Tan,
1696 R.G.H., Fillion-Robin, J.-C., Pieper, S., Aerts, H.J.W.L., 2017. Computational Radiomics
1697 System to Decode the Radiographic Phenotype. Cancer Res 77, e104–e107.
1698 https://doi.org/10.1158/0008-5472.CAN-17-0339
1699 Venegas, D.P., Fuente, M.K.D. la, Landskron, G., González, M.J., Quera, R., Dijkstra, G., Harmsen,
1700 H.J.M., Faber, K.N., Hermoso, M.A., 2019. Short Chain Fatty Acids (SCFAs)-Mediated Gut
1701 Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases.
1702 Frontiers in Immunology 10, 277. https://doi.org/10.3389/fimmu.2019.00277
1703 Vogel Ciernia, A., Careaga, M., LaSalle, J.M., Ashwood, P., 2018. Microglia from offspring of
1704 dams with allergic asthma exhibit epigenomic alterations in genes dysregulated in
1705 autism. Glia 66, 505–521. https://doi.org/10.1002/glia.23261
1706 Vogel-Ciernia, A., Wood, M.A., 2014. Examining object location and object recognition memory
1707 in mice. Current Protocols in Neuroscience 2014, 8.31.1-8.31.17.
1708 https://doi.org/10.1002/0471142301.ns0831s69
1709 Wang, Q., Garrity, G.M., Tiedje, J.M., Cole, J.R., 2007. Naïve Bayesian Classifier for Rapid
1710 Assignment of rRNA Sequences into the New Bacterial Taxonomy. Applied and
1711 Environmental Microbiology 73, 5261–5267. https://doi.org/10.1128/AEM.00062-07
1712 Weger, B.D., Gobet, C., Yeung, J., Martin, E., Jimenez, S., Betrisey, B., Foata, F., Berger, B.,
1713 Balvay, A., Foussier, A., Charpagne, A., Boizet-Bonhoure, B., Chou, C.J., Naef, F., Gachon,
1714 F., 2019. The Mouse Microbiome Is Required for Sex-Specific Diurnal Rhythms of Gene
1715 Expression and Metabolism. Cell Metab 29, 362-382.e8.
1716 https://doi.org/10.1016/j.cmet.2018.09.023
1717 Wenzel, T.J., Gates, E.J., Ranger, A.L., Klegeris, A., 2020. Short-chain fatty acids (SCFAs) alone or
1718 in combination regulate select immune functions of microglia-like cells. Mol Cell
1719 Neurosci 105, 103493. https://doi.org/10.1016/j.mcn.2020.103493
1720 Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L.D., François, R., Grolemund, G.,
1721 Hayes, A., Henry, L., Hester, J., Kuhn, M., Pedersen, T.L., Miller, E., Bache, S.M., Müller,
1722 K., Ooms, J., Robinson, D., Seidel, D.P., Spinu, V., Takahashi, K., Vaughan, D., Wilke, C.,
1723 Woo, K., Yutani, H., 2019. Welcome to the Tidyverse. Journal of Open Source Software
1724 4, 1686. https://doi.org/10.21105/joss.01686

Wirtz, S., Neurath, M.F., 2007. Mouse models of inflammatory bowel disease. Advanced Drug Delivery Reviews, Prediction of Therapeutic and Drug Delivery Outcomes Using Animal Models 59, 1073–1083. https://doi.org/10.1016/j.addr.2007.07.003

Wong, E.O.-Y., Brownlie, E.J.E., Ng, K.M., Kathirgamanathan, S., Yu, F.B., Merrill, B.D., Huang, K.C., Martin, A., Tropini, C., Navarre, W.W., 2022. The CIAMIB: a Large and Metabolically Diverse Collection of Inflammation-Associated Bacteria from the Murine Gut. mBio 13, e02949-21. https://doi.org/10.1128/mbio.02949-21

Yamane, T., Kitamura, Y., Terada, N., Matsumoto, K., 1986. Proliferative response of seminal vesicle cells to androgen and estrogen in neonatally castrated mice. Journal of Steroid Biochemistry 24, 703–708. https://doi.org/10.1016/0022-4731(86)90846-0

Yang, M., Crawley, J.N., 2009. Simple behavioral assessment of mouse olfaction. Curr Protoc Neurosci Chapter 8, Unit 8.24. https://doi.org/10.1002/0471142301.ns0824s48

Ye, Y., Pang, Z., Chen, W., Ju, S., Zhou, C., 2015. The epidemiology and risk factors of inflammatory bowel disease. Int J Clin Exp Med 8, 22529–22542.

Yi, S.Y., Barnett, B.R., Torres-Velázquez, M., Zhang, Y., Hurley, S.A., Rowley, P.A., Hernando, D., Yu, J.-P.J., 2019. Detecting Microglial Density With Quantitative Multi-Compartment Diffusion MRI. Front Neurosci 13, 81. https://doi.org/10.3389/fnins.2019.00081

Zhang, H., Schneider, T., Wheeler-Kingshott, C.A., Alexander, D.C., 2012. NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 61, 1000–1016. https://doi.org/10.1016/j.neuroimage.2012.03.072

Zhang, J., Wei, S., Zeng, Q., Wu, X., Gan, H., 2021. Prevalence and risk factors of sexual dysfunction in patients with inflammatory bowel disease: systematic review and meta-analysis. Int J Colorectal Dis 36, 2027–2038. https://doi.org/10.1007/s00384-021-03958-y

Zhao, S., Wang, J., Liu, Y., Luo, L., Zhu, Z., Li, E., Luo, J., Zhao, Z., 2019. Inflammatory Bowel Diseases Were Associated With Risk of Sexual Dysfunction in Both Sexes: A Meta-analysis. Inflamm Bowel Dis 25, 699–707. https://doi.org/10.1093/ibd/izy345

Zhou, Y., Ji, G., Yang, X., Chen, Z., Zhou, L., 2023. Behavioral abnormalities in C57BL/6 mice with chronic ulcerative colitis induced by DSS. BMC Gastroenterology 23, 84. https://doi.org/10.1186/s12876-023-02718-2

Ziętek, M., Celewicz, Z., Szczuko, M., 2021. Short-Chain Fatty Acids, Maternal Microbiota and Metabolism in Pregnancy. Nutrients 13, 1244. https://doi.org/10.3390/nu13041244



Supplemental Figure 1. DSS treatment did not alter distance travelled or exploration behavior. There are no significant main effects of treatment or interactions with treatment and sex. *A*. Total distance traveled in meters (m) in the A. elevated plus maze n=10-13/group, *B*. light-dark box task n=11-13/group and *C*. open field n=11-13/group. Total investigation time in seconds for object location memory *D*. testing and n=6-13/group. *E*. training n=6-13/group. *F*. Discrimination Index for OLM training n=6-13/group. *G*. Total investigation time in the 3 chamber social task in seconds. n=11-13/group. *H*. Total distance travelled in meters for the three chamber social task. n=11-13/group. *I.* Total investigation time in the 3 chamber novel task in seconds. n=10-13/group. *H*. Total distance travelled in meters for the three chamber novel task. n=10-13/group. Each bar and error bar represent the mean ± SEM.



Supplemental Figure 2. Effects of DSS treatment on male and female steroid levels. *A*. Three days after the last DSS treatment (P71), male serum progesterone levels were not significantly different between VEH and DSS treated males. n=4/group. *B*. Following the last behavioural test (P110), male serum progesterone levels were not significantly different between VEH and DSS treated males. n=12/group. *C-D*. Following the last behavioural test (P110), female serum progesterone (C) and testosterone (D) levels were not significantly different between VEH and DSS treated females. n=10-12/group. Androstenedione levels were non-detectable in VEH and DSS treated females. Each bar and error bar represent the mean ± SEM.


A
Females
Males
Group
Log10 Relative Abundance
0.15
0.1
0.05
0
Group
VEH
DSS
p__Actinobacteriota
p__Firmicutes
p__Proteobacteria
p__Verrucomicrobiota
c__Bacilli
c__Gammaproteobacteria
c__Verrucomicrobiae
o__Lactobacillales
o__RF39
o__Clostridia_UCG−014
o__Clostridia_vadinBB60_group
o__Clostridiales
o__Lachnospirales
o__Peptostreptococcales−Tissierellales
o__Burkholderiales
o__Verrucomicrobiales
f__Bacteroidaceae
f__Rikenellaceae
f__Erysipelatoclostridiaceae
f__Lactobacillaceae
f__RF39
f__Clostridia_UCG−014
f__Clostridia_vadinBB60_group
f__Clostridiaceae
f__Lachnospiraceae
f__Oscillospiraceae
f__[Eubacterium]_coprostanoligenes_group
f__Peptostreptococcaceae
f__Sutterellaceae
f__Akkermansiaceae
g__Bacteroides
g__Alistipes
g__Erysipelatoclostridium
g__Dubosiella
g__Faecalibaculum
g__Turicibacter
g__Lactobacillus
g__RF39
g__Clostridia UCG−014
g__Clostridia vadinBB60_group
g__Clostridium sensu_stricto_1
g__A2
g__Roseburia
g__Unclassified Lachnospiraceae
g__[Eubacterium] ventriosum_group
g__[Eubacterium] xylanophilum_group
g__Ruminococcus
g__[Eubacterium] coprostanoligenes_group
g__Romboutsia
g__Parasutterella
g__Akkermansia
s__Bacteroides acidifaciens
s__Bacteroides thetaiotaomicron
s__Alistipes_uncultured bacterium
s__Unclassified Erysipelatoclostridium
s__Dubosiella newyorkensis
s__Faecalibaculum rodentium
s__Unclassified Turicibacter
s__Unclassified Lactobacillus
s__Unclassified RF39
s__Clostridia UCG−014_unidentified
s__Unclassified Clostridia UCG−014
s__Unclassified Clostridium sensu_stricto_1
s__A2_uncultured bacterium
s__Lachnospiraceae bacterium
s__Lachnospiraceae UCG−001_uncultured bacterium
s__Lachnospiraceae_uncultured_Clostridium sp.
s__Lachnospiraceae_uncultured_uncultured bacterium
s__Roseburia_uncultured bacterium
s__Unclassified Lachnospiraceae
s__[Eubacterium] ventriosum_group_uncultured Clostridiales
s__[Eubacterium] xylanophilum_group_uncultured bacterium
s__Ruminococcus_unidentified
s__Unclassified Ruminococcus
s__gut metagenome
s__Unclassified Romboutsia
s__Unclassified Parasutterella
s__Akkermansia muciniphila
C
Acetic acid
Butyric acid
Bacillota
Roseburia
Lactobacillus
nmol/mg cecal contents
R = 0.54, p = 0.005
R = 0.76, p < 0.001
R = 0.43, p = 0.03
R = 0.73, p < 0.001
R = 0.46, p = 0.013
R = 0.72, p < 0.001
VEH
DSS
Females
Males
B
Bacillota
Lactobacillus
[Eubacterium] xylanophilum group
Akkermansia muciniphila
Relative Abundance
VEH
DSS
****
**
D
Bacteroides thetaiotaomicron
R = -0.74, p = 0.046
Testosterone (ng/mL seurm)
Relative Abundance

Supplemental Figure 3. Relative abundance of select microbial taxa correlate with cecal SCFA and serum testosterone concentrations acutely following DSS. *A*. Heatmap of differentially abundant gut bacterial taxa identified by differential abundance testing at P71. n=4-5/group. *B.* Relative abundance of Bacillota, *Lactobacillus*, *Eubacterium* xylanophilum group, and *Akkermansia muciniphila*. n=4-5/group. *C.* Correlation of relative abundance of Bacillota, *Roseburia,* and *Lactobacillus* vs. acetic and butyric acid concentrations in cecal contents at P71. *R* values from Spearman's correlation. n=5-8/group. *D*. Correlation of relative abundance of the species *Bacteroides thetaiotaomicron* vs. serum testosterone levels at P71. n=4/group. Error bars in bar plots represent SEM. **p*<0.05, ***p*<0.01, ****p*<0.001, *****p*<0.0001.



Supplemental Figure 4. Microglial Morphology Analysis. A. Correlations between individual microglial morphology metrics. B. Percentage of variance explained by each principal component (PC) after clustering the 27 features. The first 3 PCs capture ~85% of the total variance and were

used for k-means clustering. C. The correlation between each PC and individual metrics. D. The silhouette plot reveals an optimal number of 4 clusters. E. K means clustering of 4 morphologyc clusters. F. Clusters were assigned morphology names based on their relationship to each individual metric. G. Percentage of hypothalamic microglia in each cluster between treatment groups for females and males. No significant differences were identified between treatments for either sex. n=2-5/group H. Percentage of cerebral cortical microglia in each cluster between treatment groups for females and males. No significant differences were identified between treatments for either sex. n=3-5/group.



Supplemental Figure 5. Gene Expression is Not Altered in Hippocampal Tissue from DSS and VEH treated male and female mice. Expression by RT-qPCR for *Tlr4* in A. females and B. males. Expression by RT-qPCR for *Nod1* in C. females and D. males. Expression by RT-qPCR for *Nod2* in E. females and F. males. Expression by RT-qPCR for *Tnfa* in G. females and H. males. Expression by RT-qPCR for *Il1b* in I. females and J. males. Expression by RT-qPCR for *Il6* in K. females and L. males. Fold change calculated to VEH controls within each sex for each gene. n=6-8/group. Each bar and error bar represent the mean ± SEM.



Supplemental Figure 6. Orientation dispersion index (ODI) was calculated for the thalamus, frontal association cortex, and hypothalamus. Data points are mean ODI values from each sample. A significant effect of treatment was identified in the thalamus, and post-hoc tests found a significant increase for DSS females compared to VEH females. n= 25-28/group ** $p < 0.01$, Fisher's LSD test.